<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1301256597
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CO-OLMEPRESS 40 mg/25 mg F.C. Tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        OLMESARTAN MEDOXOMIL,HYDROCHLOROTHIAZIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        40,25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        66.15
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="LABORATORIOS CINFA SA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            LABORATORIOS CINFA SA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            LABORATORIOS CINFA SA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09DA08 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Co-Olmepress contains two active substances, olmesartan medoxomil and hydrochlorothiazide, that are used to treat high blood pressure (hypertension):</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Olmesartan medoxomil is &nbsp;one of a group of medicines &nbsp;called angiotensin II-receptor antagonists. It lowers blood pressure by relaxing the blood vessels.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hydrochlorothiazide is one of a group of medicines called thiazide diuretics (&ldquo;water tablets&rdquo;). It lowers blood pressure by helping the body to get rid of extra fluid by making your kidneys produce more urine.</p><p>&nbsp;</p><p>You will only be given Co-Olmepress if Olmepress (olmesartan medoxomil) alone has not adequately controlled your blood pressure. When given together, the two active substances in Co-Olmepress help to lower blood pressure more than if either of them were given alone.</p><p>&nbsp;</p><p>You may already be taking medicines to treat your high blood pressure, but your doctor may want you to take Co-Olmepress to lower it more.</p><p>&nbsp;</p><p>High blood pressure can be controlled with medicines such as Co-Olmepress tablets. Your doctor has probably also recommended that you make some changes in your lifestyle to help lower your blood pressure (for example losing weight, giving up smoking,&nbsp; reducing the amount of alcohol you drink and reducing the amount of salt in your diet). Your doctor may also have urged you to take regular exercise, such as walking or swimming. It is important to follow this advice from your doctor.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to olmesartan medoxomil or hydrochlorothiazide, or any of the other</p><p>ingredients of this medicine (listed in section 6) or substances similar to hydrochlorothiazide (sulfonamides)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are more than 3 months pregnant (It is also better to avoid avoid olmesartan medoxomil/hydrochlorothiazide in early pregnancy &ndash; see pregnancy section)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have kidney problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if &nbsp;you &nbsp;have &nbsp;diabetes &nbsp;or &nbsp;impaired &nbsp;kidney &nbsp;function &nbsp;and &nbsp;you &nbsp;are &nbsp;treated with a blood pressure lowering medicine containing aliskiren</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you suffer from low potassium, low sodium, high calcium or high uric acid levels in the blood (with symptoms of gout or kidney stones) that do not get better when treated</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you suffer from moderate or severe liver problems or yellowing of the skin and eyes (jaundice) or problems with drainage of the bile from the gallbladder (biliary obstruction</p><p>e.g. gallstones)</p><p>&nbsp;</p><p>If you think any of these apply to you, or you are unsure, do not take the tablets. Talk to your doctor first and follow the advice given.</p><p>&nbsp;</p><p>Warnings and precautions</p><p><strong>&nbsp;</strong></p><p>Talk to your doctor before using Co-Olmepress.</p><p>&nbsp;</p><p>Before you take the tablets, <strong>tell your doctor </strong>if you are taking any of the following medicines used to treat high blood pressure:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an ACE-inhibitor &nbsp;(for example enalapril, lisinopril, &nbsp;ramipril), in particular if you have diabetes-related kidney problems.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; aliskiren</p><p>&nbsp;</p><p>Your doctor may check your kidney function, blood pressure, and the amount of electrolytes (e.g. potassium) in your blood at regular intervals.</p><p>&nbsp;</p><p>See also information under the heading &ldquo;Do not take Co-Olmepress&rdquo;.</p><p>&nbsp;</p><p>Before you &nbsp;take &nbsp;the &nbsp;tablets, <strong>tell your doctor </strong>if you have any of &nbsp;the following &nbsp;health problems:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kidney transplant</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Liver diseases</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heart failure or problems with your heart valves or heart muscles</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vomiting (being sick) or diarrhoea which is severe or it goes on for several days</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment with high doses of water tablets (diuretics) or if you are on a low salt diet</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Problems with your adrenal glands (e.g. primary aldosteronism)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diabetes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lupus erythematosus (an autoimmune disease)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergies &nbsp;or asthma</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have had skin cancer or if you develop an unexpected skin lesion during the treatment. Treatment with hydrochlorothiazide, particularly long term use with high doses, may increase the risk of some types of skin and lip cancer (non-melanoma skin cancer). Protect your skin from sun exposure and UV rays while taking Co-Olmepress.</p><p><strong>Contact your doctor </strong>if you experience any of the following symptoms:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea that is severe, persistent and causes substantial weight loss. Your doctor may evaluate your symptoms and decide on how to continue your blood pressure medication.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decrease in vision or eye pain. These could be symptoms of an increase of pressure in your eye and can happen within hours to weeks of taking Co-Olmepress. This can lead to</p><p>permanent vision impairment, if not treated.</p><p>&nbsp;</p><p>Your doctor may want to see you more often and do some tests if you have any of these conditions.</p><p>&nbsp;</p><p>Olmesartan medoxomil/hydrochlorothiazide may cause a rise in blood fat levels and uric acid levels (the cause of gout &ndash; painful swelling of the joints). Your doctor will probably want to do a blood test from time to time to check these.</p><p>&nbsp;</p><p>It may change the levels of certain chemicals in your blood called electrolytes. Your doctor will probably want to do a blood test from time to time to check these. Signs of electrolyte changes are: thirst, dryness of the mouth, muscle pain or cramps, tired muscles, low blood pressure (hypotension), feeling weak, sluggish, tired, sleepy or restless, nausea, vomiting, less need to pass urine, a rapid heart rate. <strong>Tell your doctor if you notice these symptoms.</strong></p><p><strong>&nbsp;</strong></p><p>As with any medicine which reduces blood pressure, an excessive drop in blood pressure in patients with blood flow disturbances of the heart or brain could lead to a heart attack or stroke. Your doctor will therefore check your blood pressure carefully.</p><p>&nbsp;</p><p>If you are due to have tests for parathyroid function, you should stop taking Co-Olmepress before these tests are carried out.</p><p>&nbsp;</p><p>If you are a sports person, this medicine could change the results of an anti-dope test to make it positive.</p><p>&nbsp;</p><p>You must tell your doctor if you think that you are (or might become) pregnant. Olmesartan medoxomil/hydrochlorothiazide is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see pregnancy section).</p><p>&nbsp;</p><p>Children and adolescents</p><p><strong>&nbsp;</strong></p><p>Olmesartan medoxomil/hydrochlorothiazide is not recommended for children and adolescents under the age of 18.</p><p>&nbsp;</p><p>Other medicines and Co-Olmepress</p><p><strong>&nbsp;</strong></p><p>Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines.</p><p>&nbsp;</p><p>In particular, tell your doctor or pharmacist about any of the following:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other blood pressure lowering medicines (anti-hypertensives), as the effect of olmesartan medoxomil/hydrochlorothiazide can be increased.</p><p>Your doctor may need to change your dose and/or to take other precautions:</p><p>If you are taking an ACE-inhibitor or aliskiren (see also information under the headings &ldquo;Do not take Co-Olmepress&rdquo; and &ldquo;Warnings and precautions&rdquo;).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines which may alter the levels of potassium in your blood if used at the same time as olmesartan medoxomil/hydrochlorothiazide. These include:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; potassium supplements (as well as salt substitutes containing potassium)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; water tablets (diuretics)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heparin (for thinning the blood)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; laxatives</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; steroids</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; adrenocorticotrophic hormone (ACTH)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; carbenoxolone (a medicine used to treat mouth and stomach ulcers)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; penicillin G sodium (also called benzylpenicillin sodium, an antibiotic)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; certain pain killers such as aspirin or salicylates</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lithium (a medicine used to treat mood swings and some types of depression) used at the same time as olmesartan medoxomil/hydrochlorothiazide may increase the toxicity of lithium. If you have to take lithium, your doctor will measure your lithium blood levels.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Non-steroidal anti-inflammatory (NSAIDs) medicines (medicines used to relieve pain, swelling and other symptoms of inflammation, including arthritis) used at the same time as olmesartan medoxomil/hydrochlorothiazide may increase the risk of kidney failure and the effect of olmesartan medoxomil/hydrochlorothiazide can be decreased by NSAIDs.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sleeping tablets, sedatives and anti-depressant &nbsp;medicines, as using these medicines together with olmesartan medoxomil/hydrochlorothiazide may cause a sudden drop in blood pressure when standing up.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Certain medicines such as baclofen and tubocurarine, used to relax muscles.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Amifostine and some other drugs used to treat cancers, such as cyclophosphamide or methotrexate.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Colestyramine and colestipol, medicines for lowering blood fat levels.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Colesevelam hydrochloride, a drug that lowers the level of cholesterol in your blood, as the effect of olmesartan medoxomil/hydrochlorothiazide may be decreased. Your doctor may advise you to take olmesartan medoxomil/hydrochlorothiazide at least 4 hours before colesevelam hydrochloride.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anticholinergic agents, such as atropine and biperiden.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Drugs such as thioridazine, chlorpromazine, levomepromazine, trifluoperazine, cyamemazine, sulpiride, amisulpride, pimozide, sultopride, tiapride, droperidol or haloperidol, used to treat certain psychiatric disorders.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Certain medicines such as quinidine, hydroquinidine, disopyramide, amiodarone, sotalol or digitalis, used to treat heart problems.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines such as mizolastine, pentamidine, terfenadine, dofetilide, ibutilide or erythromycin injections, which may change the heart rhythm.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oral anti-diabetic medicines, such as metformin, or insulin, used to lower blood sugar.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Beta-blockers and diazoxide, medicines used to treat high blood pressure or low blood sugar, respectively, as olmesartan medoxomil/hydrochlorothiazide can enhance their blood-sugar-increasing effect.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Methyldopa, a medicine used to treat high blood pressure.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines such as noradrenaline, used to increase blood pressure and slow heart rate.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diphemanil, used to treat a slow heartbeat or reduce sweating.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines such as probenecid, sulfinpyrazone and allopurinol, used to treat gout.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Calcium supplements.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Amantadine, an anti-viral drug.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ciclosporin, a medicine used to stop rejection of organ transplants.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Certain antibiotics called tetracyclines or sparfloxacin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Amphotericin, a medicine used to treat fungal infections.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Certain antacids, used to treat too much stomach acid, such as aluminium magnesium hydroxide, as the effect of olmesartan medoxomil/hydrochlorothiazide can be slightly decreased.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cisapride, used to increase food movement in the stomach and gut.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Halofantrine, used for malaria.</p><p>&nbsp;</p><p>Co-Olmepress with food and drink</p><p><strong>&nbsp;</strong></p><p>Co-Olmepress can be taken with or without food.</p><p>&nbsp;</p><p>Take care when drinking alcohol while you are taking olmesartan medoxomil/hydrochlorothiazide, as some people feel faint or dizzy. If this happens to you, do not drink any alcohol, including wine, beer or alcopops.</p><p>&nbsp;</p><p>Black patients</p><p><strong>&nbsp;</strong></p><p>As with other similar drugs the blood pressure lowering effect of olmesartan medoxomil/hydrochlorothiazide is somewhat less in black patients.</p><p>Pregnancy and breast-feeding Pregnancy</p><p>You must tell your doctor if you think you are (or might become) pregnant. Your doctor will normally advise you to stop taking Co-Olmepress before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of olmesartan medoxomil/hydrochlorothiazide. Olmesartan medoxomil/hydrochlorothiazide is not recommended during pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if it is used after the third month of pregnancy.</p><p>&nbsp;</p><p>Breast-feeding</p><p>Tell your doctor if you are breast-feeding or about to start breast-feeding. Olmesartan medoxomil/hydrochlorothiazide is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed.</p><p>&nbsp;</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p>Driving and using machines</p><p><strong>&nbsp;</strong></p><p>You may feel sleepy or dizzy while being treated for your high blood pressure. If this happens, do not drive or use machines until the symptoms wear off. Ask your doctor for advice.</p><p>&nbsp;</p><p>Co-Olmepress contains lactose</p><p><strong>&nbsp;</strong></p><p>This medicine contains lactose (a type of sugar). If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>&nbsp;</strong></p><p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p><strong>The</strong><strong> </strong><strong>recommended</strong><strong> </strong><strong>dose</strong><strong> </strong>is one Co-Olmepress 40 mg/12.5 mg tablet a day. However, if your blood pressure is not controlled, your doctor may decide to change your dose to one Co-Olmepress 40 mg/25 mg tablet a day.</p><p>&nbsp;</p><p>Swallow the tablet with water. If possible, you should take your dose <strong>at the same time each day</strong>, for example at breakfast time. It is important to continue to take Co-Olmepress until your doctor tells you to stop.</p><p>If you take more Co-Olmepress than you should</p><p><strong>&nbsp;</strong></p><p>If you take more tablets than you should, or if a child accidentally swallows one or more, go to your doctor or nearest accident and emergency (A&amp;E) department immediately and take your medicine pack with you.</p><p>&nbsp;</p><p>If you forget to take Co-Olmepress</p><p><strong>&nbsp;</strong></p><p>If you forget to take a dose, take your normal dose on the following day as usual. Do <strong>not </strong>take a double dose to make up for a forgotten dose.</p><p>&nbsp;</p><p>If you stop taking Co-Olmepress</p><p><strong>&nbsp;</strong></p><p>It is important to continue to take Co-Olmepress unless your doctor tells you to stop.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>&nbsp;</strong></p><p>Al</p><p>Like all medicines, this medicine can cause side effects, although not everybody gets them. However, the following two side effects can be serious:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reactions that may affect the whole body, with swelling of the face, mouth and/or voice box (larynx) together with itching and rash may occur rarely. <strong>If this happens, stop taking Co-Olmepress and contact your doctor immediately.</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Olmesartan medoxomil/hydrochlorothiazide can cause the blood pressure to fall too low in susceptible individuals or as the result of an allergic reaction. Light-headedness or fainting may occur uncommonly. <strong>If this happens, stop taking Co-Olmepress, contact your doctor immediately and lie down flat.</strong></p><p>&nbsp;</p><p>&nbsp;</p><p>Co-Olmepress is a combination of two active substances and the following information firstly gives the other side effects reported so far with the combination Co-Olmepress&nbsp; (besides those already mentioned above) and, secondly, those which are known about for the separate active substances.</p><p>&nbsp;</p><p>These are the other side effects known about so far with Co-Olmepress:</p><p>If these side effects occur, they are often mild and <strong>you do not need to stop your treatment. Common side effects (may affect up to 1 in 10 people):</strong></p><p>Dizziness, weakness, headache, tiredness, chest pain, swelling of ankles, feet, legs, hands or arms.</p><p>&nbsp;</p><p>Uncommon side effects (may affect up to 1 in 100 people):</p><p>Fluttering of the heartbeat (palpitations), rash, eczema, vertigo, cough, indigestion, abdominal pain, nausea, vomiting, diarrhoea, muscle cramps and muscular pain, pain in joints, arms and legs, back pain, erection difficulties in men, blood in urine.</p><p>Some changes in blood test results have also been seen uncommonly and include:</p><p>Rise in blood fat levels, rise in blood urea or uric acid, rise in creatinine, rise or decrease in blood potassium levels, rise in blood calcium levels, rise in blood sugar, increase in levels of liver function. Your doctor will know about these from a blood test and will tell you if you need to do anything.</p><p>&nbsp;</p><p>Rare side effects (may affect up to 1 in 1,000 people):</p><p>Feeling unwell, disturbances in consciousness, skin lumps (wheals), acute kidney failure.</p><p>&nbsp;</p><p>Some changes in blood test results have also been seen in rare cases and include:</p><p>Rise in blood urea nitrogen, decrease in haemoglobin and haematocrit values. Your doctor will know about these from a blood test and will tell you if you need to do anything.</p><p>&nbsp;</p><p>Further side effects reported with use of olmesartan medoxomil or hydrochlorothiazide alone, but not with Co-Olmepress or in a higher frequency:</p><p><strong>&nbsp;</strong></p><p><strong>Olmesartan</strong><strong> </strong><strong>medoxomil:</strong></p><p><strong>&nbsp;</strong></p><p><strong>Common </strong><strong>side</strong><strong> </strong><strong>effects (may affect up to 1 in 10 people):</strong></p><p>Bronchitis, cough, runny or stuffy nose, sore throat, abdominal pain, indigestion, diarrhoea, nausea, gastroenteritis, pain in the joints or bones, back pain, blood in urine, urinary tract infection, flu-like symptoms, pain.</p><p>&nbsp;</p><p>Some changes in blood test results have also been seen commonly and include:</p><p>Rise in blood fat levels, rise in blood urea or uric acid, increase in levels of liver and muscle function.</p><p>&nbsp;</p><p>Uncommon side effects (may affect up to 1 in 100 people):</p><p>Quick allergic reactions that may affect the whole body and may cause breathing problems as well as&nbsp; a rapid fall of blood pressure that may even lead to fainting (anaphylactic reactions), swelling of the face, angina (pain or uncomfortable feeling in the chest; known as angina pectoris), feeling unwell, allergic skin rash, itching, exanthema (skin eruption), skin lumps (wheals).</p><p>Some changes in blood test results have also been seen uncommonly and include: Reduced numbers of a type of blood cell, known as platelets (thrombocytopenia).</p><p>&nbsp;</p><p>Rare side effects (may affect up to 1 in 1,000 people):</p><p>Impaired kidney function, lack of energy.</p><p>&nbsp;</p><p>Some changes in blood test results have also been seen rarely and include: Increase in blood potassium.</p><p>&nbsp;</p><p>Hydrochlorothiazide:</p><p><strong>&nbsp;</strong></p><p><strong>Very</strong><strong> </strong><strong>common </strong><strong>side</strong><strong> </strong><strong>effects (may affect more than 1 in 10 people):</strong></p><p>Changes in blood results including: Increase in blood fat and uric acid levels.</p><p>&nbsp;</p><p>Common side effects (may affect up to 1 in 10 people):</p><p>Feeling confused, abdominal pain, stomach upset, bloated feeling, diarrhoea, nausea, vomiting, constipation, excretion of glucose into the urine.</p><p>&nbsp;</p><p>Some changes in blood results have also been seen and include:</p><p>Increase &nbsp;in &nbsp;blood &nbsp;creatinine, &nbsp;urea, &nbsp;calcium &nbsp;and &nbsp;sugar &nbsp;levels, &nbsp;decrease &nbsp;in &nbsp;blood &nbsp;chloride, potassium, magnesium and sodium levels. Increase of serum amylase (hyperamylasaemia).</p><p>&nbsp;</p><p>Uncommon side effects (may affect up to 1 in 100 people):</p><p>Decreased or loss of appetite, severe difficulty breathing, anaphylactic skin reactions (hypersensitivity reactions), worsening of pre-existing myopia, erythema, skin reactions to light, itching, purplish spots or patches on the skin due to small haemorrhages (purpura), skin lumps (wheals).</p><p>&nbsp;</p><p>Rare side effects (may affect up to 1 in 1,000 people):</p><p>Swollen and sore salivary glands, decreased number of white blood cells, decreased number of blood platelets, anaemia, bone marrow damage, restlessness, feeling &lsquo;down&rsquo; or depressed, problems sleeping, feeling un-interested (apathy), tingling and numbness, fits (convulsions), objects you look at appearing yellow, blurred vision, dry eyes, irregular heartbeat, inflammation of the blood vessels, blood clots (thrombosis or embolism), inflammation of the lung, fluid accumulation in the lungs, inflammation of the pancreas, jaundice, infection in the gall bladder, symptoms of lupus erythematosus such as rash, joint pains and cold hands and fingers, allergic skin reactions, peeling and blistering of the skin, non-infectious&nbsp; inflammation of the kidney (interstitial nephritis), fever, muscle weakness (sometimes causing impaired movement).</p><p>&nbsp;</p><p>Very rare side effects (may affect up to 1 in 10,000 people):</p><p>Electrolyte &nbsp;disturbance &nbsp;leading &nbsp;to &nbsp;an &nbsp;abnormally &nbsp;depleted &nbsp;level &nbsp;of &nbsp;chloride &nbsp;in &nbsp;the &nbsp;blood (hypochloraemic alkalosis), blockage in the gut (paralytic ileus).</p><p>&nbsp;</p><p><strong>Not</strong><strong> </strong><strong>known (frequency cannot be estimated from the available data): </strong>Decrease in vision or eye pain (possible signs of acute angle-closure glaucoma). Skin and lip cancer (Non-melanoma skin cancer).</p><p>&nbsp;</p><p>Reporting of side effects:</p><p>If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not store above 30&deg;C.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton and on the blister strip as EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substances are:</p><p>Each film-coated tablet contains 40 mg olmesartan medoxomil and 25 mg hydrochlorothiazide.</p><p>The other ingredients are:</p><p>Microcrystalline cellulose, lactose monohydrate, povidone, hydroxypropylcellulose, magnesium stearate, OpadryY-1-7000, yellow iron oxide, red iron oxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Co-Olmepress 40 mg/25 mg are pale pink, oblong, film-coated tablet with logo D4 on one side.

Co-Olmepress 40 mg/25 mg is supplied in packages containing 28 tablets (7-tablets blister packs).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>LABORATORIOS CINFA, S.A.</p><p>Olaz-Chipi,10. Pol&iacute;gono Industrial Areta,</p><p>31620 Huarte-Pamplona (Navarra) &ndash; Spain</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                November 2018.


            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">يحتوي كو- أولميبريس على مادتين فعَّالتين وهما أولميسارتان ميدوكسوميل وهيدروكلوروثيازيد، اللتان تستخدمان في علاج ارتفاع ضغط الدم (ضغط الدم المرتفع):</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تنتمي مادة أولميسارتان إلى فئة من العقاقير تعرف بمضادات مستقبلات الأنجيوتنسين الثاني، والتي تعمل على خفض ضغط الدم من خلال إرخاء الأوعية الدموية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تنتمي مادة هيدروكلوروثيازيد إلى فئة من العقاقير تُعرف بمُدِرَّات البول الثيازيدية (ويطلق عليها أيضاً اسم &quot;أقراص المياه&quot;) التي تعمل على خفض ضغط الدم من خلال مساعدة الكُلى على التخلص من السوائل الزائدة و زيادة إدرار البول.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يستعمل دواء كو- أولميبرس في حالة عدم قدرة دواء أولميبرس (أولميسارتان ميدوكسوميل) وحده على ضبط ضغط الدم. تعمل المادتان الفعالتان لدواء كو- أولميبرس معاً على خفض ضغط الدم بدرجة أكبر من تناول كل مكون على حدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">حتى وإن كنت تتناول بالفعل علاجاً لخفض ضغط الدم، قد يصف لك الطبيب أقراص كو- أولميبرس وذلك لخفض ضغط الدم بدرجة أكبر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن التحكم في ضغط الدم المرتفع بتناول الأدوية مثل أقراص كو- أولميبرس. في الأغلب قد ينصحك طبيبك بإدخال بعض التغييرات على نمط حياتك للمساعدة في خفض ضغط الدم (على سبيل المثال إنقاص الوزن والإقلاع عن التدخين وتقليل مقدار المشروبات الكحولية التي تتناولها وخفض كمية الملح في نظامك الغذائي). قد ينصحك الطبيب أيضاً بممارسة التمارين الرياضية بشكل منتظم مثل السير أو السباحة. من المهم أن تتبع هذه النصائح التي يقدمها إليك الطبيب.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;لا تتناول كو- أولميبرس:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك حساسية من مادة أولميسارتان ميدوكسوميل أو مادة هيدروكلوروثيازيد أو أي من مكونات الدواء</p><p dir="RTL">الأخرى (المدرجة في قسم 6) أو المواد الأخرى المشابهة لمادة هيدروكلوروثيازيد (المشتقة من السلفوناميد).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تجاوزت فترة الحمل ثلاثة أشهر (يُفضل أيضاً عدم تناول أولميسارتان ميدوكسوميل/ هيدروكلوروثيازيد في مراحل الحمل الأولى - انظر القسم الخاص بالحمل).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشكلات شديدة في الكُلى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصاباً بداء السكري أو اعتلال في وظائف الكُلى وتتم معالجتك بدواء خافض لضغط الدم يحتوي على مادة الأليسكيرين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من انخفاض مستوى البوتاسيوم أو الصوديوم في الدم، أو ارتفاع مستوى الكالسيوم أو حمض اليوريك في الدم (مع ظهور أعراض الإصابة بالنقرس أو تكوُّن حصوات في الكُلى) والتي لا تتحسن عند الخضوع للعلاج.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشكلات شديدة في الكبد أو اصفراراً في الجلد والعينين (الصفراء) أو مشكلات في تصريف العصارة الصفراوية من المرارة (انسداد القناة الصفراوية مثل حصوات المرارة).</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا انطبقت عليك أيٌ من الحالات السابقة -حتى وإن كنت غير متأكد- فاستشر الطبيب، ولا تتناول الدواء. تحدث إلى طبيبك واتبع النصائح التي يقدمها لك.</p><p dir="RTL">&nbsp;</p><p>الاحتياطات والتحذيرات</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">تحدث إلى طبيبك قبل تناول كو- أولميبرس.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قبل البدء في تناول هذه الأقراص، <strong>يجب إخبار الطبيب </strong>إذا كنت تتناول أياً من الأدوية التالية لعلاج ضغط الدم المرتفع:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دواء مثبط للإنزيم المحول للأنجيوتنسين (مثل أنالابريل، ليزينوبريل، راميبريل)، وخاصة إذا كنت تعاني من مشاكل في الكُلى مرتبطة بداء السكري.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أليسكيرين</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يفحص طبيبك وظائف الكُلى وضغط الدم ومستوى الأملاح في الدم (مثل البوتاسيوم) على فترات زمنية منتظمة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">انظر أيضاً المعلومات الواردة تحت عنوان &quot;لا تتناول كو- أولميبرس&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قبل البدء في تناول هذا الدواء، <strong>أخبر طبيبك </strong>إذا كنت تعاني من أيٌّ من المشكلات الصحية التالية:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات بسيطة إلى متوسطة في الكُلى أو إذا كنت قد خضعت مؤخراً لجراحة زرع كلية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمراض الكبد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قصور في القلب أو مشكلات في صمامات القلب أو عضلة القلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيء أو الإسهال الشديد الذي قد يستمر لعدة أيام.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العلاج بجرعات كبيرة من أقراص المياه (مدرات البول) أو كنت تتبع حمية غذائية منخفضة الأملاح.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات في الغدد الكظرية (مثل مرض الألدوستيرونية الأولية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; داء السكري.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الذئبة الحمراء الجهازية (أحد أمراض المناعة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحساسية أو الربو.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد أصبت بسرطان الجلد أو إذا ظهرت عليك تقرحات جلدية غير متوقعة أثناء العلاج. تناول هيدروكلوروثيازيد، وخاصة على المدى الطويل وبجرعات كبيرة قد يزيد من خطر الإصابة ببعض أنواع سرطان الجلد و الشفاه (سرطان الجلد الغير قاتم). يجب حماية الجلد من التعرض لأشعة الشمس و الأشعة فوق البنفسجية أثناء تناول كو- أولميبرس.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>اتصل بطبيبك</strong> إذا أُصبت بأي من الأعراض التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال شديد ودائم أدى إلى فقدان الوزن بشكل ملحوظ. سيقَيِّم الطبيب هذه الأعراض ويقرر مايلزم فيما يتعلق بتناول أدوية ضغط الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف في حِدة الإبصار أو ألم في العين. قد تكون هذه أعراض تراكم السوائل في الطبقة الوعائية للعين (الانصباب المشيمي) أو قد تكون أعراض زيادة الضغط في العين ويمكن أن تحدث خلال ساعات أو أسابيع من تناول كو- أولميبرس. وقد يؤدي ذلك إلى ضعف دائم في الرؤية، إذا لم يتم علاجه.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يرغب الطبيب في متابعة حالتك بشكل متكرر و قد يطلب منك عمل بعض الاختبارات إذا كنت تعاني من هذه الأعراض.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يسبب أولميسارتان ميدوكسوميل/ هيدروكلوروثيازيد زيادة مستوى الدهون وحمض اليوريك بالدم (الذي يؤدي إلى الإصابة بالنقرس - تورم المفاصل مع شعور بالألم). قد يطلب منك الطبيب عمل اختبارات دم من وقت لآخر لمتابعة هذه النسب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يعمل هذا الدواء على تغيير مستوى بعض المواد الكيماوية في الدم والتي تعرف بالإلكتروليتات. قد يطلب منك الطبيب عمل اختبارات دم من وقت لآخر لمتابعة هذه النسب. هناك أعراض تشير إلى تغير مستوى الإلكتروليتات وهي العطش وجفاف الفم وآلام وتقلصات وتعب بالعضلات وانخفاض ضغط الدم والشعور بالوهن والتعب والخمول والنعاس والقلق والغثيان والقيء وعدم الرغبة في التبول وزيادة معدل ضربات القلب. <strong>أخبر طبيبك على الفور إذا ظهرت عليك هذه الأعراض.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">مثل كل الأدوية الأخرى التي تعالج ضغط الدم المرتفع، قد يؤدي الانخفاض الشديد في ضغط الدم لدى المرضى المصابين باضطرابات في تدفق الدم إلى القلب أو المخ إلى حدوث أزمة قلبية أو سكتة دماغية. وبالتالي سيقوم طبيبك بفحص ضغط الدم بعناية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان من المفترض أن تقوم بإجراء اختبارات لفحص وظائف الغدة الجار درقية يجب التوقف عن تناول أقراص كو- أولميبرس قبل إجراء هذه الاختبارات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تمارس الرياضة، فإن هذا الدواء قد يعطي نتائج إيجابية في اختبار الكشف عن المنشطات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب أن تخبري طبيبكِ إذا كنتِ تعتقدين في وجود حمل (أو تخططين لذلك). لا يُنصح باستعمال&nbsp; أولميسارتان ميدوكسوميل/ هيدروكلوروثيازيد في مراحل الحمل الأولى ويجب عدم تناوله إذا تجاوزت فترة حملك ثلاثة أشهر، فمن المحتمل أن يُلحق ضرراً بالغاً بطفلك في حالة استعماله في هذه المرحلة (انظر القسم الخاص بالحمل).</p><p dir="RTL">&nbsp;</p><p>الأطفال والمراهقون</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">لا يتم إعطاء أولميسارتان ميدوكسوميل/ هيدروكلوروثيازيد للأطفال والمراهقين الذين تقل أعمارهم عن 18 عاماً.</p><p dir="RTL">&nbsp;</p><p>التفاعلات مع الأدوية الأخرى</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">أخبر الطبيب أو الصيدلي إذا كنت تتناول أو إذا كنت تناولت مؤخراً أو من المحتمل أن تتناول أي أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">و بالأخص أخبر طبيبك إذا كنت تتناول أياً من الأدوية التالية:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية الأخرى الخافضة لضغط الدم، حيث يمكن أن يزيد تأثير أولميسارتان ميدوكسوميل/ هيدروكلوروثيازيد.</p><p dir="RTL">قد يحتاج طبيبك إلى تغيير الجرعة و/أو اتباع احتياطات أخرى:</p><p dir="RTL">إذا كنت تتناول أحد مثبطات الإنزيم المحول للأنجيوتنسين أو مادة أليسكيرين (انظر المعلومات الواردة تحت العنوانين &quot;لا تتناول كو- أولميبرس&quot; &nbsp;و&quot;الاحتياطات والتحذيرات&quot;).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي قد تغير مستوى البوتاسيوم في الدم في حال تناولها مع أولميسارتان ميدوكسوميل/ هيدروكلوروثيازيد. وتشمل هذه الأدوية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مكملات البوتاسيوم (وكذلك بدائل الملح التي تحتوي على البوتاسيوم).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أقراص الماء (مدرات البول).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الهيبارين (لعلاج تجلط الدم).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المُلينات.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الستيرويدات.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الهرمون المنشط للغدة الكظرية (ACTH).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;كاربينوكوزولون (يستخدم لعلاج قرح المعدة و الفم).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بنسيللين ج صوديوم (مضاد حيوي يعرف أيضاً ببنزيل بنسيللين الصوديوم).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مسكنات الألم مثل الأسبرين أو الساليسيلات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الليثيوم (دواء يُستخدم لعلاج التقلبات المزاجية وبعض أنواع الاكتئاب) إذ يؤدي استخدامه في نفس الوقت مع أولميسارتان ميدوكسوميل/ هيدروكلوروثيازيد إلى زيادة سمية الليثيوم. إذا كان هناك ضرورة لتناول الليثيوم فسيقوم الطبيب بقياس مستويات الليثيوم في الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الالتهاب غير الستيروئيدية (NSAIDs) (الأدوية المستخدمة لتخفيف الألم والتورم و أعراض الالتهاب الأخرى، بما في ذلك التهاب المفاصل) إذ قد يؤدي تناولها في نفس الوقت مع أولميسارتان ميدوكسوميل/ هيدروكلوروثيازيد إلى زيادة خطر الإصابة بالفشل الكلوي ويمكن أن يقل تأثير أولميسارتان ميدوكسوميل/ هيدروكلوروثيازيد باستخدام مضادات الالتهاب غير الستيروئيدية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأقراص المنومة والمُهدئة ومضادات الاكتئاب إذ يؤدي تناولها في نفس الوقت مع أولميسارتان ميدوكسوميل/ هيدروكلوروثيازيد إلى حدوث انخفاض مفاجئ في ضغط الدم عند الوقوف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية التي تستخدم لإرخاء العضلات مثل باكلوفين وتيوبوكورارين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أميفوستين والأدوية الأخرى التي تستخدم لعلاج السرطان مثل سيكلوفوسفاميد أو ميثوتريكسات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الكوليسترامين والكوليستيبول، أدوية تُستخدم في خفض مستويات الدهون في الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هيدروكلوريد كوليسيفيلام، عقار يستخدم لخفض مستوى الكوليسترول في الدم، و قد يؤدي إلى خفض تأثير أولميسارتان ميدوكسوميل/ هيدروكلوروثيازيد. قد ينصحك طبيبك بتناول أولميسارتان ميدوكسوميل/ هيدروكلوروثيازيد قبل عقار هيدروكلوريد كوليسيفيلام بأربع ساعات على الأقل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات&nbsp; الكولين مثل الأتروبين والبيبريدين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية الأخرى مثل ثيوريدازين، كلوربرومازين، ليفوميبرومازين، ترايفلوبيرازين،&nbsp; سياميمازين، سلبيريد، اميسلبرايد، بيموزيد، سولتوبريد، تيابريد، دروبيريدول أو هالوبيريدول، المستخدمة في علاج بعض الاضطرابات النفسية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية المستخدمة في علاج مشكلات القلب مثل الكينيدين، الهيدروكينيدين، الديسوبيراميد، الأميودارون، السوتاتول أو الديجيتاليس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي قد تؤثر في معدل ضربات القلب مثل الميزولاستين، البينتاميدين، التيرفينادين، الدوفيتيليد، حقن الإيبوتيليد أو الإريثروميسين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تؤخذ عن طريق الفم لعلاج داء السكري مثل الميتفورمين أو الأنسولين والتي تعمل على خفض مستويات السكر في الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حاصرات بيتا و الديازوكسيد، يستخدم الأول لعلاج ضغط الدم المرتفع والثاني لعلاج انخفاض مستوى السكر في الدم، حيث يزداد تأثير هذه الأدوية التي تعمل على رفع مستوى السكر في الدم عند تناولها مع أولميسارتان ميدوكسوميل/ هيدروكلوروثيازيد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميثيل دوبا المستخدم في علاج ارتفاع ضغط الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تسبب ارتفاع ضغط الدم وانخفاض معدل ضربات القلب مثل نورأدرينالين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ديفيمانيل الذي يستخدم لعلاج انخفاض معدل ضربات القلب أو الحد من التعرق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لعلاج النقرس مثل بروبينسيد وسولفينبيرازون وألوبيورينول.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مكملات الكالسيوم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأمانتادين، عقار مضاد للفيروسات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السيكلوسبورين، وهو دواء يُستخدم في عمليات زراعة الأعضاء لمنع رفض الجسم للعضو المزروع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض المضادات الحيوية مثل تتراسايكلن أو سبارفلوكساسين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمفوتيريسين المستخدم في علاج العدوى الفطرية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض مضادات الحموضة المستخدمة لعلاج الإفراز الزائد لحمض المعدة مثل هيدروكسيد ماغنيسيوم ألومنيوم، إذ قد تؤدي إلى خفض تأثير أولميسارتان ميدوكسوميل/ هيدروكلوروثيازيد بشكل طفيف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيسابريد الذي يعمل على زيادة حركة الطعام داخل المعدة والأمعاء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هالوفانترين دواء يُستخدم لعلاج الملاريا.</p><p dir="RTL">&nbsp;</p><p>تناول&nbsp; كو- أولميبرس مع الطعام والشراب</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">يمكن تناول كو- أولميبرس مع الطعام أو بدونه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب توخي الحذر عند تناول المشروبات الكحولية أثناء العلاج بأولميسارتان ميدوكسوميل/ هيدروكلوروثيازيد إذ قد يشعر البعض بالدوار أو الإغماء. إذا ظهرت عليك هذه الأعراض يجب الامتناع عن تناول المشروبات الكحولية.</p><p dir="RTL">&nbsp;</p><p>المرضى ذوي البشرة السوداء</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">شأنه شأن الأدوية المماثلة الأخرى يكون المفعول الذي يحدثه أولميسارتان ميدوكسوميل/ هيدروكلوروثيازيد في خفض ضغط الدم أقل في المرضى ذوي البشرة السوداء.</p><p>الحمل والإرضاع</p><p>&nbsp;الحمل</p><p dir="RTL">يجب أن تخبري طبيبكِ إذا كنت تعتقدين أنك حامل (أو تخططين لذلك).&nbsp; سينصحكِ الطبيب عادة بالتوقف عن تناول كو- أولميبرس قبل أن تصبحي حاملاً أو بمجرد معرفتك أنك حامل وسينصحكِ بتناول دواء آخر بدلاً من أولميسارتان ميدوكسوميل/ هيدروكلوروثيازيد. لا يُنصح باستعمال أولميسارتان ميدوكسوميل/ هيدروكلوروثيازيد أثناء الحمل، ويجب عدم تناوله إذا تجاوزت فترة حملك ثلاثة أشهر، فمن المحتمل أن يُلحق ضرراً بالغاً بطفلك في حالة استعماله في بعد الشهر الثالث من الحمل.</p><p dir="RTL">&nbsp;</p><p>الإرضاع</p><p dir="RTL">أخبري طبيبك إذا ما كنتِ تُرضعين أو على وشك الإرضاع. لا يُنصح باستعمال أولميسارتان ميدوكسوميل/ هيدروكلوروثيازيد من قبل الأمهات أثناء فترة الإرضاع، وقد يختار طبيبك علاجاً آخر إذا كنت ترغبين في الإرضاع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت حاملاً أو تعتقدين أنك حامل أو كنتِ تخططين للحمل فاستشيري الطبيب أو الصيدلي قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p>القيادة وتشغيل الآلات</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">قد تشعر بالنعاس أو الدوار خلال فترة علاج ضغط الدم المرتفع. في حال حدوث ذلك تجنب القيادة أو استخدام الآلات حتى تختفي هذه الأعراض.&nbsp; استشر الطبيب.</p><p dir="RTL">&nbsp;</p><p>يحتوي كو- أولميبرس على اللاكتوز</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">يحتوي هذا الدواء على اللاكتوز (أحد أنواع السكر). إذا أخبرك الطبيب بأنك تعاني من حساسية لبعض أنواع السكر فاستشر طبيبك قبل تناول هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">تناول هذا الدواء دائماً حسب وصف الطبيب. استشر طبيبك أو الصيدلي إذا لم تكن متأكداً.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة الموصى بها </strong>هي قرص واحد كو - أولميبرس 40 ملجم/ 12,5 ملجم يومياً. ومع ذلك، إذا لم يتم التحكم في ضغط الدم قد يقرر طبيبك تغيير الجرعة إلى قرص واحد من كو &ndash; أولميبرس 40 ملجم/ 25 ملجم في اليوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ابتلع الأقراص مع الماء. إن أمكن،<strong> تناول جرعتك اليومية في نفس الوقت من كل يوم،</strong> على سبيل المثال في وقت الإفطار. من المهم مواصلة العلاج بدواء كو- أولميبرس حتى يخبرك الطبيب بخلاف ذلك.</p><p dir="RTL">&nbsp;</p><p>تناول جرعة زائدة من كو- أولميبرس</p><p dir="RTL">في حال تناول جرعة زائدة من الأقراص أو ابتلاع طفلك بعض الأقراص عن طريق الخطأ توجَّه إلى الطبيب أو قسم الحوادث والطوارئ بأقرب مستشفى على الفور واصطحب معك عبوة الدواء.</p><p dir="RTL">&nbsp;</p><p>إذا نسيت تناول كو- أولميبرس</p><p dir="RTL">إذا نسيت تناول إحدى الجرعات فتناول الجرعة المحددة في اليوم التالي في موعدها الطبيعي. <strong>لا </strong>تتناول جرعة مضاعفة لتعويض الجرعة التي نسيتها.</p><p dir="RTL">&nbsp;</p><p>إذا توقفت عن تناول كو- أولميبرس</p><p dir="RTL">من المهم مواصلة العلاج بدواء كو- أولميبرس حتى يخبرك الطبيب بخلاف ذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى عن طريقة استخدام هذا الدواء فاسال الطبيب أو الصيدلي.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل كل الأدوية، قد يسبب هذا الدواء آثاراً جانبية، ولكنها لا تظهر بالضرورة على كل من يتناوله.</p><p dir="RTL">فيما يلي اثنين من الآثار الجانبية التي قد تشكل خطورة:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات الحساسية -نادراً ما تحدث- التي تؤثر على الجسم بالكامل، حيث يحدث تورم بالوجه و/أو الفم و/أو الحنجرة مع الإصابة بالحكة والطفح الجلدي. <strong>في حال حدوث ذلك توقف عن تناول كو-أولميبرس واتصل بطبيبك على الفور.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن أن يتسبب أولميسارتان ميدوكسوميل/ هيدروكلوروثيازيد في هبوط ضغط الدم هبوطاً شديداً في الأشخاص المعرضين لذلك أو كنتيجة لأحد تفاعلات الحساسية. قد يؤدي ذلك إلى حدوث دوار أو إغماء (هذه الآثار غير شائعة الحدوث). <strong>في حال حدوث ذلك توقف عن تناول كو-أولميبرس، واتصل بطبيبك على الفور واستلقِ على ظهرك.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">يحتوي كو- أولميبرس على مادتين فعالتين. و فيما يلي الآثار الجانبية التي سجلت حتى الآن المرتبطة بأقراص كو- أولميبرس (إلى جانب الآثار السابقة المشار إليها أعلاه) ثم يليها الآثار الجانبية الخاصة بكل مادة فعالة على حدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p>فيما يلي الآثار الجانبية الأخرى المرتبطة بدواء كو- أولميبرس والمعروفة حتى الآن:</p><p dir="RTL">&nbsp;في حال حدوث هذه الآثار الجانبية، فغالباً ما تكون بسيطة <strong>ولن تستلزم إيقاف العلاج. </strong></p><p dir="RTL"><strong>آثار جانبية شائعة (قد تؤثر في شخص واحد من كل 10 أشخاص):</strong></p><p dir="RTL">دوار، ضعف، صداع، شعور بالتعب، ألم في الصدر، تورم الكاحلين أو القدمين أو الساقين أو اليدين أو الذراعين.</p><p dir="RTL">&nbsp;</p><p>آثار جانبية غير شائعة (قد تؤثر في شخص واحد من كل 100 شخص):</p><p dir="RTL">زيادة معدل ضربات القلب (خفقان القلب)، طفح جلدي، إكزيما، دوار، سعال، عسر هضم، ألم في منطقة البطن، غثيان، قيء، إسهال، آلام و تقلص بالعضلات، آلام المفاصل والذراعين والساقين، ألم الظهر، صعوبة الانتصاب لدى الرجال، وجود دم في البول.</p><p dir="RTL">لوحظ أيضاً حدوث بعض التغيرات غير الشائعة في نتائج اختبار الدم وتشمل ما يلي:</p><p dir="RTL">ارتفاع مستوى الدهون في الدم، ارتفاع مستوى حمض اليوريك أو اليوريا في الدم، ارتفاع مستوى الكرياتينين، ارتفاع أو انخفاض مستوى البوتاسيوم في الدم، ارتفاع مستوى الكالسيوم في الدم، أو ارتفاع مستوى السكر في الدم، أو زيادة في نتائج اختبارات وظائف الكبد. يتعرف الطبيب على هذه الآثار من خلال اختبارات الدم ويخبرك بما ينبغي عليك القيام به.</p><p dir="RTL">&nbsp;</p><p>آثار جانبية نادرة (قد تؤثر في شخص واحد من كل 1,000 شخص):</p><p dir="RTL">الشعور بالإعياء، اضطرابات في الوعي، كتل جلدية (بثور)، فشل كلوي حاد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لوحظ في حالات نادرة حدوث بعض التغيرات في نتائج اختبار الدم وتشمل ما يلي:</p><p dir="RTL">&nbsp;زيادة نسبة تركيز النيتروجين في اليوريا بالدم، انخفاض مستويات الهيموجلوبين والهيماتوكريت في الدم. يتعرف الطبيب على هذه الأعراض من خلال اختبارات الدم ويخبرك بما ينبغي عليك القيام به.</p><p dir="RTL">&nbsp;</p><p>سجلت آثار جانبية أخرى عند العلاج بكل مادة فعالة على حدة (مادة أولميسارتان ميدوكسوميل أو مادة هيدروكلوروثيازيد) ولكن ليس مع كو- أولميبرس، أو لوحظ تكرار حدوث هذه الآثار الجانبية بشكل أكبر عند تناول كل مادة فعالة على حدة:</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أولميسارتان ميدوكسوميل:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>آثار جانبية شائعة (قد تؤثر في شخص واحد من كل 10 أشخاص):</strong></p><p dir="RTL">التهاب شعبي، سعال، رشح أو انسداد في الأنف، احتقان الحلق، ألم في منطقة البطن، عسر هضم، إسهال، غثيان، التهاب في المعدة والأمعاء، آلام المفاصل أو العظام، ألم الظهر، وجود دم في البول، عدوى الجهاز البولي، أعراض شبيهة بالإنفلونزا، ألم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لوحظ أيضاً حدوث بعض التغيرات في نتائج اختبار الدم (بصورة شائعة) وتشمل ما يلي:</p><p dir="RTL">زيادة مستوى الدهون في الدم، زيادة مستوى حمض اليوريا أو اليوريك في الدم، زيادة في نتائج اختبارات وظائف الكبد والعضلات.</p><p dir="RTL">&nbsp;</p><p>آثار جانبية غير شائعة (قد تؤثر في شخص واحد من كل 100 شخص):</p><p dir="RTL">تفاعلات حساسية سريعة من شأنها التأثير في الجسم بالكامل وقد تتسبب في حدوث مشكلات في التنفس بالإضافة إلى هبوط سريع في ضغط الدم الأمر الذي قد يؤدي إلى الإغماء (تفاعلات تأقية)، تورُّم الوجه، ذبحة صدرية (شعور بالألم أو عدم الراحة في الصدر وهو ما يعرف بالذبحة الصدرية)، شعور بالإعياء، طفح جلدي، حكة، &nbsp;كتل جلدية (بثور).</p><p dir="RTL">&nbsp;</p><p dir="RTL">لوحظ أيضاً حدوث بعض التغيرات في نتائج اختبار الدم (بصورة غير شائعة) وتشمل ما يلي:</p><p dir="RTL">نقصاً في نوع معين من خلايا الدم التي تُعرف بالصفائح الدموية (قلة الصفائح الدموية).</p><p>&nbsp;</p><p>آثار جانبية نادرة (قد تؤثر في شخص واحد من كل 1,000 شخص):</p><p dir="RTL">اعتلال في وظائف الكلى، نقص الطاقة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لوحظ أيضاً حدوث بعض التغيرات في نتائج اختبار الدم (بصورة نادرة) وتشمل ما يلي:</p><p dir="RTL">زيادة مستوى البوتاسيوم في الدم.</p><p dir="RTL">&nbsp;</p><p>هيدروكلوروثيازيد:</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>آثار جانبية أكثر شيوعاً (تؤثر في أكثر من شخص واحد من كل 10 أشخاص)</strong></p><p dir="RTL">تغير في نتائج اختبارات الدم وتشمل: زيادة في مستوى الدهون بالدم وحمض اليوريك.</p><p dir="RTL">&nbsp;</p><p>آثار جانبية شائعة (قد تؤثر في شخص واحد من كل 10 أشخاص):</p><p dir="RTL">توتر، ألم في منطقة البطن، اضطراب في المعدة، شعور بالانتفاخ، إسهال، غثيان، قيء، إمساك، إفراز الجلوكوز في البول.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لوحظ أيضاً حدوث بعض التغيرات في نتائج اختبار الدم وتشمل ما يلي:</p><p dir="RTL">زيادة في مستويات الكيراتين واليوريا والكالسيوم والسكر في الدم، انخفاض مستويات الكلوريد والبوتاسيوم والماغنيسيوم والصوديوم في الدم. زيادة إنزيم الأميليز في الدم.</p><p dir="RTL">&nbsp;</p><p>آثار جانبية غير شائعة (قد تؤثر في شخص واحد من كل 100 شخص):</p><p dir="RTL">فقدان الشهية، صعوبة في التنفس، تفاعلات تأقية (تفاعلات فرط الحساسية)، تدهور حالة قصر النظر، الحمامى، تحسس البشرة عند التعرض للضوء وحكة، ظهور بقع ذات لون أرجواني على البشرة نتيجة لحدوث نزيف بسيط (الفرفرية)، كتل جلدية (بثور).</p><p dir="RTL">&nbsp;</p><p>آثار جانبية نادرة (قد تؤثر في شخص واحد من كل 1,000 شخص):</p><p dir="RTL">تورم الغدد اللعابية والتهابها، انخفاض عدد خلايا الدم البيضاء، انخفاض عدد الصفائح الدموية، الأنيميا، تلف النخاع العظمي، أرق، شعور بالإحباط، اضطرابات في نوم، شعور باللامبالاة، شعور بالوخز والتخدير، نوبات مَرضية (تشنجات)، رؤية الأشياء بلون أصفر، رؤية ضبابية، جفاف العينين، عدم انتظام معدل ضربات القلب، التهاب الأوعية الدموية، جلطات الدم (تخثر الدم أو انسداد الأوعية الدموية)، التهاب الرئة، تراكم السوائل في الرئة، التهاب البنكرياس، الصفراء، عدوى في المرارة، أعراض الإصابة بالذئبة الحمراء مثل الطفح الجلدي وألم المفاصل وبرودة اليدين والأصابع، تفاعلات الحساسية، تقشر الجلد أو ظهور بثور متقرحة به، التهاب الكلى غير المُعدي (التهاب الكلية الخلالي)، حمى، ضعف العضلات (تعوق الحركة في بعض الأحيان).</p><p dir="RTL">&nbsp;</p><p>آثار جانبية نادرة للغاية (قد تؤثر في شخص واحد من كل 10,000 شخص):</p><p dir="RTL">عدم توازن الأملاح (الإلكتروليتات) مما يؤدي إلى انخفاض مستوى الكلوريد في الدم على نحو غير طبيعي (القلاء الناتج عن نقص كلوريد الدم)، انسداد الأمعاء (علوص شللي).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية غير معروفة </strong>(<strong>لا يمكن تقدير معدل تكرارها من البيانات المتاحة</strong>)<strong>:</strong></p><p dir="RTL">ضعف في حِدة الإبصار أو ألم في العين (علامات محتملة لتراكم السوائل في الطبقة الوعائية للعين (الانصباب المشيمي) أو زرق انسداد الزاوية الحادة).</p><p dir="RTL">سرطان الجلد والشفاه (سرطان الجلد الغير قاتم).</p><p dir="RTL">&nbsp;</p><p>الإبلاغ عن ظهور آثار جانبية</p><p dir="RTL">إذا ظهر عليك أي آثار جانبية فاستشر الطبيب أو الصيدلي. ويشمل هذا أي آثار جانبية محتملة غير واردة في هذه النشرة. يمكنك الإبلاغ عن الآثار الجانبية مباشرة (انظر التفاصيل أدناه). الإبلاغ عن ظهور آثار جانبية يساهم في زيادة المعلومات المتعلقة بسلامة هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ هذا الدواء بعيداً عن متناول الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحفظ في درجة حرارة لا تزيد عن 30 ْم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا يستعمل هذا الدواء بعد انتهاء تاريخ الصلاحية الموضح على العلبة والشريط بعد كلمة EXP . يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من هذا الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا ينبغي التخلص من أي أدوية عن طريق مياه الصرف أو النفايات المنزلية. اسأل الصيدلي عن طريقة التخلص من الأدوية التي لم تعد تستعملها. تساعد هذه التدابير في حماية البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;كو- أولميبرس 40 ملجم/ 25 ملجم: يحتوي كل قرص مغلف على 40 ملجم أولميسارتان ميدوكسوميل</p><p dir="RTL">و25 ملجم هيدروكلوروثيازيد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أما المكونات الأخرى فهي:</p><p dir="RTL">&nbsp;</p><p dir="RTL">سليلوز دقيق البلورات، مونوهيدرات اللاكتوز، بوفيدون، هيدروكسي بروبيل السيلولوز، ستيارات الماغنسيوم، أوبادري Y-1-7000، أكسيد الحديد الأصفر، أكسيد الحديد الأحمر.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أقراص كو-أولميبرس 40 ملجم/ 25 ملجم هي أقراص مغلفة ذات لون وردي فاتح، مستطيلة الشكل، ومحفور على أحد جانبيها رمز D4.</p><p dir="RTL">&nbsp;</p><p dir="RTL">كو-أولميبرس 40 ملجم/ 25 ملجم يتوفر في عبوة تحتوي على 28 قرصاً (4 شرائط في كل شريط 7 أقراص).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مختبرات سينفا، ش.م.</p><p dir="RTL">شارع أولاز شيبي، 10 منطقة بوليغنو الصناعية،</p><p dir="RTL">31620 أوارتي (نافارا) - إسبانيا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            نوفمبر 2018
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Co-Olmepress 40 mg/25 mg film­coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Co-Olmepress 40 mg/25 mg film­coated tablets:
Each film­coated tablet contains 40 mg olmesartan medoxomil and 25 mg hydrochlorothiazide. Excipient(s) with known effect:
Each film­coated tablet contains 196.40 mg lactose monohydrate. For the full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film­coated tablets.
Co-Olmepress 40 mg/25 mg film­coated tablets:
Pale pink, oblong, film-coated tablet with logo D4 on one side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of essential hypertension.</p><p>Co-Olmepress fixed dose combination is indicated in adult patients whose blood pressure is not adequately controlled on olmesartan medoxomil alone.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><!--[if gte vml 1]><v:shape id="_x0000_s1026" style='position:absolute;
 margin-left:86.35pt;margin-top:13.6pt;width:1.3pt;height:1pt;z-index:-251658240;
 mso-position-horizontal-relative:page;mso-position-vertical-relative:text'
 coordsize="26,20" o:allowincell="f" path="m,7hhl25,7e" filled="f"
 strokeweight=".29886mm">
 <v:path arrowok="t"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="4" height="2" src="file:///C:/Users/Moustafa/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png" /><u>Posology</u></p><p><em>Adults</em></p><p>Olmesartan medoxomil/hydrochlorothiazide is not for use as initial therapy, but in patients whose blood pressure is not adequately controlled by 20 mg olmesartan medoxomil alone. Co-Olmepress is administered once daily, with or without food.</p><p>When clinically appropriate, direct change from monotherapy with 20 mg olmesartan medoxomil to the fixed combination may be considered, taking into account that the antihypertensive effect of olmesartan medoxomil is maximal by about 8 weeks after initiating therapy (see section 5.1). Dose titration of the individual components is recommended:</p><p>20 mg olmesartan medoxomil/12.5 mg hydrochlorothiazide may be administered in patients whose blood pressure is not adequately controlled by the optimal monotherapy olmesartan medoxomil 20 mg alone.</p><p>20 mg olmesartan medoxomil/ 25 mg hydrochlorothiazide may be administered in patients whose blood pressure is not adequately controlled by 20 mg olmesartan medoxomil/ 12.5 mg hydrochlorothiazide.</p><p><em>Elderly (age 65 years or over)</em></p><p>In elderly people the same dosage of the combination is recommended as for adults.</p><p><em>Renal impairment</em></p><p>When olmesartan medoxomil/hydrochlorothiazide is used in patients with mild to moderate renal impairment (creatinine clearance of 30 &ndash; 60 mL/min) periodic monitoring of renal function is advised (see section 4.4). Olmesartan medoxomil/hydrochlorothiazide is contraindicated in patients with severe renal impairment (creatinine clearance &lt; 30 mL/min) (see section 4.3).</p><p><em>Hepatic impairment</em></p><p>Olmesartan medoxomil/hydrochlorothiazide should be used with caution in patients with mild to moderate hepatic impairment (see sections 4.4, 5.2). In patients with moderate hepatic impairment, an initial dose of 10 mg olmesartan medoxomil once daily is recommended and the maximum dose should not exceed 20 mg once daily. Close monitoring of blood pressure and renal function is advised in hepatically-impaired patients who are receiving diuretics and/or other antihypertensive agents. There is no experience of olmesartan medoxomil in patients with severe hepatic impairment.</p><p>&nbsp;</p><p>Olmesartan medoxomil/hydrochlorothiazide should not be used in patients with severe hepatic impairment (see sections 4.3, 5.2), cholestasis and biliary obstruction (see section 4.3).</p><p><em>Paediatric population</em></p><p>The safety and efficacy of olmesartan medoxomil/hydrochlorothiazide in children and adolescents below 18 years has not been established. No data are available.</p><p><u>Method of administration</u></p><p>The tablet should be swallowed with a sufficient amount of fluid (e.g. one glass of water). The tablet should not be chewed and should be taken at the same time each day.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substances, to any of the excipients listed in section 6.1 or to other sulfonamide-derived substances (since hydrochlorothiazide is a sulfonamide-derived medicinal product).
Severe renal impairment (creatinine clearance < 30 mL/min).
Refractory hypokalaemia, hypercalcaemia, hyponatraemia and symptomatic hyperuricaemia. Severe hepatic impairment, cholestasis and biliary obstructive disorders.
2nd and 3rd trimester of pregnancy (see sections 4.4 and 4.6).
The concomitant use of olmesartan medoxomil/hydrochlorothiazide with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 mL/min/1.73 m2) (see sections 4.5 and 5.1).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptomatic hypotension, especially after the first dose, may occur in patients who are volume and/or sodium depleted by vigorous diuretic therapy, dietary salt restriction, diarrhoea or vomiting. Such conditions should be corrected before the administration of olmesartan medoxomil/hydrochlorothiazide.</p><p>Other conditions with stimulation of the renin-angiotensin-aldosterone system:</p><p>In patients whose vascular tone and renal function depend predominantly on the activity of the renin-angiotensin- aldosterone system (e.g. patients with severe congestive heart failure or underlying renal disease, including renal artery stenosis), treatment with medicinal products that affect this system has been associated with acute hypotension, azotaemia, oliguria or, rarely, acute renal failure.</p><p>Renovascular hypertension:</p><p>There is an increased risk of severe hypotension and renal insufficiency when patients with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney are treated with medicinal products that affect the renin- angiotensin-aldosterone &nbsp;system.</p><p>Renal impairment and kidney transplantation:</p><p>Olmesartan medoxomil/hydrochlorothiazide should not be used in patients with severe renal impairment (creatinine clearance &lt; 30 mL/min) (see section 4.3). No dosage adjustment is necessary in patients with mild to moderate renal impairment (creatinine clearance is &ge; 30 mL/min, &lt; 60 mL/min). However, in such patients olmesartan medoxomil/hydrochlorothiazide should be administered with caution and periodic monitoring of serum potassium, creatinine and uric acid levels is recommended. Thiazide diuretic- associated azotaemia may occur in patients with impaired renal function. If progressive renal impairment becomes evident, careful reappraisal of therapy is necessary, with consideration given to discontinuing diuretic therapy. There is no experience of the administration of olmesartan medoxomil/hydrochlorothiazide in patients with a recent kidney transplantation.</p><p>Dual blockade of the renin-angiotensin-aldosterone system (RAAS):</p><p>There is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including acute renal failure). Dual blockade of RAAS through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is therefore not recommended (see sections 4.5 and 5.1).</p><p>If dual blockade therapy is considered absolutely necessary, this should only occur under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure.</p><p>ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic nephropathy.</p><p>Hepatic impairment:</p><p>There is currently no experience of olmesartan medoxomil in patients with severe hepatic impairment. Furthermore, minor alterations of fluid and electrolyte balance during thiazide therapy may precipitate hepatic coma in patients with impaired hepatic function or progressive liver disease. Therefore care should be taken in patients with mild to moderate hepatic impairment (see section 4.2). Use of olmesartan medoxomil/hydrochlorothiazide in patients with severe hepatic impairment, cholestasis and biliary obstruction is contraindicated (see sections 4.3, 5.2).</p><p>&nbsp;</p><p>Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy:</p><p>As with other vasodilators, special caution is indicated in patients suffering from aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.</p><p>Primary aldosteronism:</p><p>Patients with primary aldosteronism generally will not respond to anti-hypertensive medicinal products acting through inhibition of the renin-angiotensin system. Therefore, the use of olmesartan medoxomil/hydrochlorothiazide is not recommended in such patients.</p><p>Metabolic and endocrine effects:</p><p>Thiazide therapy may impair glucose tolerance. In diabetic patients dosage adjustments of insulin or oral hypoglycaemic agents may be required (see section 4.5). Latent diabetes mellitus may become manifest during thiazide therapy.</p><p>Increases in cholesterol and triglyceride levels are undesirable effects known to be associated with thiazide diuretic therapy.</p><p>Hyperuricaemia may occur or frank gout may be precipitated in some patients receiving thiazide therapy.</p><p>Electrolyte imbalance:</p><p>As for any patient receiving diuretic therapy, periodic determination of serum electrolytes should be performed at appropriate intervals.</p><p>Thiazides, including hydrochlorothiazide, can cause fluid or electrolyte imbalance (including hypokalaemia, hyponatraemia and hypochloraemic alkalosis). Warning signs of fluid or electrolyte imbalance are dryness of the mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pain or cramps, muscular fatigue, hypotension, oliguria, tachycardia, and gastrointestinal disturbances such as nausea or vomiting (see section 4.8).</p><p>The risk of hypokalaemia is greatest in patients with cirrhosis of the liver, in patients experiencing brisk diuresis, in patients who are receiving inadequate oral intake of electrolytes and in patients receiving concomitant therapy with corticosteroids or ACTH (see section 4.5).</p><p>Conversely, due to antagonism at the angiotensin-II receptors (AT1) through the olmesartan medoxomil component of Co-Olmepress hyperkalaemia may occur, especially in the presence of renal impairment and/or heart failure, and diabetes mellitus. Adequate monitoring of serum potassium in patients at risk is recommended. Potassium-sparing diuretics, potassium supplements or potassium-containing salt substitutes and other medicinal products that may increase serum potassium levels (e.g. heparin) should be co-administered cautiously with olmesartan medoxomil/hydrochlorothiazide (see section 4.5).</p><p>There is no evidence that olmesartan medoxomil would reduce or prevent diuretic-induced hyponatraemia. Chloride deficit is generally mild and usually does not require treatment.</p><p>Thiazides may decrease urinary calcium excretion and cause an intermittent and slight elevation of serum calcium in the absence of known disorders of calcium metabolism. Hypercalcaemia may be evidence of hidden hyperparathyroidism. Thiazides should be discontinued before carrying out tests for parathyroid function.</p><p>Thiazides have been shown to increase the urinary excretion of magnesium, which may result in hypomagnesaemia. Dilutional hyponatraemia may occur in oedematous patients in hot weather.</p><p>Lithium:</p><p>As with other medicinal products containing angiotensin II receptor antagonists and thiazide in combination, the coadministration of olmesartan medoxomil/hydrochlorothiazide and lithium is not recommended (see section 4.5).</p><p>Sprue-like enteropathy:</p><p>In very rare cases severe, chronic diarrhoea with substantial weight loss has been reported in patients taking olmesartan few months to years after drug initiation, possibly caused by a localized delayed hypersensitivity reaction. Intestinal biopsies of patients often demonstrated villous atrophy. If a patient develops these symptoms during treatment with olmesartan, and in the absence of other apparent etiologies, olmesartan treatment should be immediately discontinued and should not be restarted. If diarrhoea does not improve during the week after the discontinuation, further specialist (e.g. a gastro-enterologist) advice should be considered.</p><p>Acute Myopia and Secondary Angle-Closure Glaucoma:</p><p>Hydrochlorothiazide, a sulfonamide, can cause an idiosyncratic reaction, resulting in acute transient myopia and acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to weeks of drug initiation. Untreated acute angle-closure glaucoma can lead to permanent vision loss. The primary treatment is to discontinue hydrochlorothiazide as rapidly as possible. Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle- closure glaucoma may include a history of sulfonamide or penicillin allergy.</p><p>Non-melanoma skin cancer:</p><p>An increased risk of non-melanoma skin cancer (NMSC) [basal cell carcinoma (BCC) and squamous cell carcinoma (SCC)] with increasing cumulative dose of hydrochlorothiazide (HCTZ) exposure has been observed in two epidemiological studies based on the Danish National Cancer Registry. Photosensitizing actions of HCTZ could act as a possible mechanism for NMSC.</p><p>&nbsp;</p><p>Patients taking HCTZ should be informed of the risk of NMSC and advised to regularly check their skin for any new lesions and promptly report any suspicious skin lesions. Possible preventive measures such as limited exposure to sunlight and UV rays and, in case of exposure, adequate protection should be advised to the patients in order to minimize the risk of skin cancer. Suspicious skin lesions should be promptly examined potentially including histological examinations of biopsies. The use of HCTZ may also need to be reconsidered in patients who have experienced previous NMSC (see also section 4.8).</p><p>Ethnic differences:</p><p>As with all other angiotensin II receptor antagonists, the blood pressure lowering effect of olmesartan medoxomil is somewhat less in black patients than in non-black patients, possibly because of a higher prevalence of low-renin status in the black hypertensive population.</p><p>Anti-doping test:</p><p>Hydrochlorothiazide contained in this medicinal product could produce a positive analytic result in an anti-doping test.</p><p>Pregnancy:</p><p>Angiotensin II receptor antagonists should not be initiated during pregnancy. Unless continued angiotensin II receptor antagonists therapy is considered essential, patients planning pregnancy should be changed to alternative anti- hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with angiotensin II receptor antagonists should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6)</p><p>Other:</p><p>In general arteriosclerosis, in patients with ischaemic heart disease or ischaemic cerebrovascular disease, there is always a risk that excessive blood pressure decrease could result in a myocardial infarction or stroke.</p><p>Hypersensitivity reactions to hydrochlorothiazide may occur in patients with or without a history of allergy or bronchial asthma, but are more likely in patients with such a history.</p><p>Exacerbation or activation of systemic lupus erythematosus has been reported with the use of thiazide diuretics.</p><p>This medicinal product contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp- lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Potential interactions related to both olmesartan medoxomil and hydrochlorothiazide:</strong></p><p>Concomitant use not recommended</p><p><em>Lithium:</em></p><p>Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin converting enzyme inhibitors and, rarely, with angiotensin II receptor antagonists. In addition, renal clearance of lithium is reduced by thiazides and consequently the risk of lithium toxicity may be increased.</p><p>Therefore use of olmesartan medoxomil/hydrochlorothiazide and lithium in combination is not recommended (see section 4.4). If use of the combination proves necessary, careful monitoring of serum lithium levels is recommended.</p><p>Concomitant use requiring caution</p><p><em>Baclofen:</em></p><p>Potentiation of antihypertensive effect may occur.</p><p><em>Non-steroidal anti-inflammatory medicinal products:</em></p><p>NSAIDs (i.e. acetylsalicylic acid (&gt; 3 g/day), COX-2 inhibitors and non-selective NSAIDs) may reduce the antihypertensive effect of thiazide diuretics and angiotensin II receptor antagonists.</p><p>In some patients with compromised renal function (e.g. dehydrated patients or elderly people with compromised renal function) the co-administration of angiotensin II receptor antagonists and agents that inhibit cyclo-oxygenase may result in further deterioration of renal function, including possible acute renal failure, which is usually reversible. Therefore, the combination should be administered with caution, especially in elderly people. Patients should be adequately hydrated and consideration should be given to monitoring of renal function after initiation of concomitant therapy and periodically thereafter.</p><p>Concomitant use to be taken into account</p><p><em>Amifostine:</em></p><p>Potentiation of antihypertensive effect may occur.</p><p><em>Other antihypertensive agents:</em></p><p>The blood pressure lowering effect of olmesartan medoxomil/hydrochlorothiazide can be increased by concomitant use of other antihypertensive medicinal products.</p><p><em>Alcohol, barbiturates, narcotics or antidepressants:</em></p><p><em>&nbsp;</em></p><p>Potentiation of orthostatic hypotension may occur.</p><p>Potential interactions related to olmesartan medoxomil:</p><p>Concomitant use not recommended</p><p><em>ACE-inhibitors, angiotensin II receptor blockers or aliskiren:</em></p><p>Clinical trial data has shown that dual blockade of the renin-angiotensin-aldosterone-system (RAAS) through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).</p><p><em>Medicinal products affecting potassium levels:</em></p><p>Based on experience with the use of other medicinal products that affect the renin-angiotensin system, concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products that may increase serum potassium levels (e.g. heparin, ACE inhibitors) may lead to increases in serum potassium (see section 4.4). If medicinal products which affect potassium levels are to be prescribed in combination with olmesartan medoxomil/hydrochlorothiazide, monitoring of potassium plasma levels is advised.</p><p><em>Bile acid sequestering agent colesevelam:</em></p><p>Concurrent administration of the bile acid sequestering agent colesevelam hydrochloride reduces the systemic exposure and peak plasma concentration of olmesartan and reduces t1/2. Administration of olmesartan medoxomil at least 4 hours prior to colesevelam hydrochloride decreased the drug interaction effect. Administering olmesartan medoxomil at least 4 hours before the colesevelam hydrochloride dose should be considered (see section 5.2).</p><p>Additional information</p><p>After treatment with antacid (aluminium magnesium hydroxide), a modest reduction in bioavailability of olmesartan was observed.</p><p>Olmesartan medoxomil had no significant effect on the pharmacokinetics or pharmacodynamics of warfarin or the pharmacokinetics of digoxin.</p><p>Coadministration of olmesartan medoxomil with pravastatin had no clinically relevant effects on the pharmacokinetics of either component in healthy subjects.</p><p>Olmesartan had no clinically relevant inhibitory effects on human cytochrome P450 enzymes 1A1/2, 2A6, 2C8/9, 2C19, 2D6, 2E1 and 3A4 <em>in vitro</em>, and had no or minimal inducing effects on rat cytochrome P450 activities. No clinically relevant interactions between olmesartan and medicinal products metabolised by the above cytochrome P450 enzymes are expected.</p><p>&nbsp;</p><p>Potential interactions related to hydrochlorothiazide:</p><p>Concomitant use not recommended</p><p><em>Medicinal products affecting potassium levels:</em></p><p>The potassium-depleting effect of hydrochlorothiazide (see section 4.4) may be potentiated by the coadministration of other medicinal products associated with potassium loss and hypokalaemia (e.g. other kaliuretic diuretics, laxatives, corticosteroids, ACTH, amphotericin, carbenoxolone, penicillin G sodium or salicylic acid derivatives). Such concomitant use is therefore not recommended.</p><p>Concomitant use requiring caution</p><p><em>Calcium salts:</em></p><p>Thiazide diuretics may increase serum calcium levels due to decreased excretion. If calcium supplements must be prescribed, serum calcium levels should be monitored and calcium dosage adjusted accordingly.</p><p><em>Cholestyramine and colestipol resins:</em></p><p>Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins.</p><p><em>Digitalis glycosides:</em></p><p>Thiazide-induced hypokalaemia or hypomagnesaemia may favour the onset of digitalis-induced cardiac arrhythmias.</p><p><em>Medicinal products affected by serum potassium disturbances:</em></p><p>Periodic monitoring of serum potassium and ECG is recommended when olmesartan medoxomil/hydrochlorothiazide is administered with medicinal products affected by serum potassium disturbances (e.g. digitalis glycosides and antiarrhythmics) and with the following torsades de pointes (ventricular tachycardia)-inducing medicinal products (including some antiarrhythmics), hypokalaemia being a predisposing factor to torsades de pointes (ventricular tachycardia):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Class Ia antiarrythmics (e.g. quinidine, hydroquinidine, disopyramide).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Class III antiarrythmics (e.g. amiodarone, sotalol, dofetilide, ibutilide).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Some antipsychotics (e.g. thioridazine, chlorpromazine, levomepromazine, trifluoperazine, cyamemazine, sulpiride, sultopride, amisulpride, tiapride, pimozide, haloperidol, droperidol).</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Others (e.g. bepridil, cisapride, diphemanil, erythromycin IV, halofantrin, mizolastin, pentamidine, sparfloxacin, terfenadine, vincamine IV).</p><p><em>Non-depolarizing skeletal muscle relaxants (e.g. tubocurarine):</em></p><p>The effect of nondepolarizing skeletal muscle relaxants may be potentiated by hydrochlorothiazide.</p><p><em>Anticholinergic agents (e.g. atropine, biperiden):</em></p><p>Increase of the bioavailability of thiazide-type diuretics by decreasing gastrointestinal motility and stomach emptying rate.</p><p><em>Antidiabetic medicinal products (oral agents and insulin):</em></p><p>The treatment with a thiazide may influence the glucose tolerance. Dosage adjustment of the antidiabetic medicinal product may be required (see section 4.4).</p><p><em>Metformin:</em></p><p>Metformin should be used with caution because of the risk of lactic acidosis induced by possible functional renal failure linked to hydrochlorothiazide.</p><p><em>Beta-blockers and diazoxide:</em></p><p>The hyperglycaemic effect of beta-blockers and diazoxide may be enhanced by thiazides.</p><p><em>Pressor amines (e.g. noradrenaline):</em></p><p>The effect of pressor amines may be decreased.</p><p><em>Medicinal products used in the treatment of gout (e.g. probenecid, sulfinpyrazone and allopurinol)</em>:</p><p>Dosage adjustment of uricosuric medicinal products may be necessary since hydrochlorothiazide may raise the level of serum uric acid. Increase in dosage of probenecid or sulfinpyrazone may be necessary. Coadministration of a thiazide may increase the incidence of hypersensitivity reactions to allopurinol.</p><p><em>Amantadine:</em></p><p>Thiazides may increase the risk of adverse effects caused by amantadine.</p><p><em>Cytotoxic agents (e.g. cyclophosphamide, methotrexate):</em></p><p>Thiazides may reduce the renal excretion of cytotoxic medicinal products and potentiate their myelosuppressive effects.</p><p><em>Salicylates:</em></p><p>In case of high dosages of salicylates hydrochlorothiazide may enhance the toxic effect of the salicylates on the central nervous system.</p><p><em>Methyldopa:</em></p><p>There have been isolated reports of haemolytic anaemia occurring with concomitant use of hydrochlorothiazide and methyldopa.</p><p><em>Cyclosporine:</em></p><p>Concomitant treatment with cyclosporine may increase the risk of hyperuricaemia and gout-type complications.</p><p><em>Tetracyclines:</em></p><p>Concomitant administration of tetracyclines and thiazides increases the risk of tetracycline-induced increase in urea. This interaction is probably not applicable to doxycycline.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><!--[if gte vml 1]><v:shape id="_x0000_s1026" style='position:absolute;
 margin-left:168.35pt;margin-top:13.6pt;width:1pt;height:1pt;z-index:-251657216;
 mso-position-horizontal-relative:page;mso-position-vertical-relative:text'
 coordsize="20,20" o:allowincell="f" path="m,7hhl4,7e" filled="f"
 strokeweight=".29886mm">
 <v:path arrowok="t"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="2" height="2" src="file:///C:/Users/Moustafa/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png" /><u>Pregnancy (see section 4.3</u>)</p><p>Given the effects of the individual components in this combination product on pregnancy, the use of olmesartan medoxomil/hydrochlorothiazide is not recommended during the first trimester of pregnancy (see section 4.4). The use of olmesartan medoxomil/hydrochlorothiazide is contra-indicated during the 2nd and 3rd trimester of pregnancy (see sections 4.3 and 4.4).</p><p><em>Olmesartan medoxomil:</em></p><p>The use of angiotensin II receptor antagonists is not recommended during the first trimester of pregnancy (see section 4.4). The use of angiotensin II receptor antagonists is contra-indicated during the 2nd and 3rd trimester of pregnancy (see sections 4.3 and 4.4).</p><p>Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Whilst there is no controlled epidemiological data on the risk with angiotensin II receptor antagonists, similar risks may exist for this class of drugs. Unless continued angiotensin receptor blocker therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with angiotensin II receptor antagonists should be stopped immediately, and, if appropriate, alternative therapy should be started.</p><p>&nbsp;</p><p>Exposure to angiotensin II receptor antagonists therapy during the 2nd and 3rd trimesters is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia). (See also 5.3 &ldquo;Preclinical safety data&rdquo;.)</p><p>Should exposure to angiotensin II receptor antagonists have occurred from the 2nd trimester of pregnancy, ultrasound check of renal function and skull is recommended.</p><p>Infants whose mothers have taken angiotensin II receptor antagonists should be closely observed for hypotension (see also sections 4.3 and 4.4).</p><p><em>Hydrochlorothiazide:</em></p><p>There is limited experience with hydrochlorothiazide during pregnancy, especially during the first trimester. Animal studies are insufficient.</p><p>Hydrochlorothiazide crosses the placenta. Based on the pharmacological mechanism of action of hydrochlorothiazide its use during the 2nd and 3rd trimester may compromise foeto-placental perfusion and may cause foetal and neonatal effects like icterus, disturbance of electrolyte balance and thrombocytopenia.</p><p>Hydrochlorothiazide should not be used for gestational oedema, gestational hypertension or preeclampsia due to the risk of decreased plasma volume and placental hypoperfusion, without a beneficial effect on the course of the disease.</p><p>Hydrochlorothiazide should not be used for essential hypertension in pregnant women except in rare situations where no other treatment could be used.</p><p><u>Breast-feeding</u></p><p><em>Olmesartan medoxomil:</em></p><p>Because no information is available regarding the use of olmesartan medoxomil/hydrochlorothiazide during breast-feeding, olmesartan medoxomil/hydrochlorothiazide is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.</p><p><em>Hydrochlorothiazide:</em></p><p>Hydrochlorothiazide is excreted in human milk in small amounts. Thiazides in high doses causing intense diuresis can inhibit the milk production.</p><p>The use of olmesartan medoxomil/hydrochlorothiazide during breast-feeding is not recommended. If olmesartan medoxomil/hydrochlorothiazide is used during breast-feeding, doses should be kept as low as possible.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Olmesartan medoxomil/hydrochlorothiazide has minor or moderate influence on the ability to drive and use machines. Dizziness or fatigue may occasionally occur in patients taking antihypertensive therapy, which may impair the ability to react.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most commonly reported adverse reactions during treatment with olmesartan medoxomil/hydrochlorothiazide are headache (2.9%), dizziness (1.9%) and fatigue (1.0%).</p><p>Hydrochlorothiazide may cause or exacerbate volume depletion which may lead to electrolyte imbalance (see section 4.4).</p><p>In clinical trials involving 1155 patients treated with olmesartan medoxomil/ hydrochlorothiazide combinations at dosages of 20/12.5 mg or 20/25 mg and 466 patients treated with placebo for periods of up to 21 months, the overall frequency of adverse reactions on olmesartan medoxomil/hydrochlorothiazide combination therapy was similar to that on placebo.</p><p>Discontinuations due to adverse reactions were also similar for olmesartan medoxomil/hydrochlorothiazide 20/12.5 mg - 20/25 mg (2%) and placebo (3%). The frequency of adverse reactions on olmesartan medoxomil/ hydrochlorothiazide overall relative to placebo appeared to be unrelated to age (&lt; 65 years versus &ge; 65 years), gender or race although the frequency of dizziness was somewhat increased in patients aged &ge; 75 years.</p><p>In addition, the safety of olmesartan medoxomil/hydrochlorothiazide as a high dose combination was investigated in clinical trials in 3709 patients receiving olmesartan medoxomil in combination with hydrochlorothiazide in the dose strengths 40 mg/12.5 mg and 40 mg/25 mg.</p><p>Adverse reactions from olmesartan medoxomil/hydrochlorothiazide in clinical trials, post-authorisation safety studies and spontaneous reporting are summarised in the below table as well as adverse reactions from the individual components olmesartan medoxomil and hydrochlorothiazide based on the known safety profile of these substances.</p><p>The following terminologies have been used in order to classify the occurrence of adverse reactions: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000), not known (cannot be estimated from the available data).</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:586px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>MedDRA</p><p>System Organ Class</p></td><td rowspan="2" style="vertical-align:top"><p>Adverse reactions</p></td><td style="vertical-align:top"><p>Frequency</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Olmesartan medoxomil/hydrochlorothiazide</p></td><td style="vertical-align:top"><p>Olmesartan</p></td><td style="vertical-align:top"><p>HCTZ</p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Sialadenitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</p></td><td style="vertical-align:top"><p>Non-melanoma skin cancer (Basal cell carcinoma and Squamous cell carcinoma)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td rowspan="6" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Aplastic anaemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Bone marrow depression</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Haemolytic anaemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Leukopenia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Neutropenia/ Agranulocytosis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Anaphylactic reactions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="14" style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Anorexia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Glykosuria</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hypercalcaemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hypercholesterolaemia</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Hyperglycaemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hyperkalaemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hypertriglyceridaemia</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Hyperuricaemia</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Hypochloraemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hypochloraemic alcalosis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Hypokaliaemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hypomagnesaemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hyponatriaemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hyperamylasaemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Apathy</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Depression</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Restlessness</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Sleep disturbances</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="8" style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Confusional state</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Convulsions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Disturbances in consciousness (such as loss of consciousness)</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Dizziness/light-headedness</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Loss of appetite</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Paraesthesia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Postural dizziness</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Somnolence</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Syncope</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Lacrimation decreased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Transient blurred vision</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Worsening of pre-existing myopia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Acute myopia, acute angle- closure glaucoma</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Xanthopsia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top"><p>Vertigo</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Angina pectoris</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac arrhythmias</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Palpitations</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Embolism</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Hypotension</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Necrotising angiitis (vasculitis, cutaneous vasculitis)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Orthostatic hypotension</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Thrombosis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="8" style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Bronchitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cough</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Dyspnoea</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Interstitial pneumonia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Pharyngitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Pulmonary oedema</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory distress</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Rhinitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="10" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Abdominal pain</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhoea</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Dyspepsia</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastric irritation</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Gastroenteritis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Meteorism</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Pancreatitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Paralytic ileus</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Sprue-like enteropathy (see section 4.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Hepato-biliary disorders</p></td><td style="vertical-align:top"><p>Acute cholecystitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Jaundice (intrahepatic cholestasic icterus)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="14" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Allergic dermatitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Anaphylactic skin reactions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Angioneurotic oedema</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cutaneous lupus erythematodes-like reactions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Eczema</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Erythema</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Exanthem</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Photosensitivity reactions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Pruritus</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Purpura</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Reactivation of cutaneous lupus erythematodes</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Toxic epidermal necrolysis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Urticaria</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="9" style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Arthralgia</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Arthritis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Back pain</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Muscle spasm</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Muscular weakness</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Myalgia</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Pain in extremity</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Paresis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Skeletal pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="6" style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Acute renal failure</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Haematuria</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Interstitial nephritis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Renal insufficiency</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Renal dysfunction</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Urinary tract infection</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive system and</p></td><td style="vertical-align:top"><p>Erectile dysfunction</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>breast disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="11" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Asthenia</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Chest pain</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Face oedema</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Fever</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Influenza-like symptoms</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Lethargy</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Malaise</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Peripheral oedema</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Weakness</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="16" style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Alanine aminotransferase increased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Aspartate aminotransferase increased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Blood calcium increased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Blood creatinine increased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Blood creatine phosphokinase increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Blood glucose increased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Blood haematocrit decreased</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Blood haemoglobin decreased</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Blood lipids increased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Blood potassium decreased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Blood potassium increased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Blood urea increased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Blood urea nitrogen increased</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Blood uric acid increased</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gamma glutamyl transferase increased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hepatic enzymes increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>Single cases of rhabdomyolysis have been reported in temporal association with the intake of angiotensin II receptor blockers.</p><p>Non-melanoma skin cancer: Based on available data from epidemiological studies, cumulative dose-dependent association between HCTZ and NMSC has been observed (see also sections 4.4 and 5.1).</p><p><u>Reporting</u><u> </u><u>of</u><u> </u><u>suspected</u><u> </u><u>adverse</u><u> </u><u>reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions.</p><p>&nbsp;</p><p>To report any side effect(s):</p><p>&minus; The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Toll free phone: 8002490000</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No specific information is available on the effects or treatment of olmesartan medoxomil/hydrochlorothiazide overdose. The patient should be closely monitored, and the treatment should be symptomatic and supportive. Management depends upon the time since ingestion and the severity of the symptoms. Suggested measures include induction of emesis and/or gastric lavage.</p><p>Activated charcoal may be useful in the treatment of overdose. Serum electrolytes and creatinine should be monitored frequently. If hypotension occurs, the patient should be placed in a supine position, with salt and volume replacements given quickly.</p><p>The most likely manifestations of olmesartan medoxomil overdose are expected to be hypotension and tachycardia; bradycardia might also occur. Overdose with hydrochlorothiazide is associated with electrolyte depletion (hypokalaemia, hypochloraemia) and dehydration resulting from excessive diuresis. The most common signs and symptoms of overdose are nausea and somnolence. Hypokalaemia may result in muscle spasm and/or accentuate cardiac arrhythmias associated with the concomitant use of digitalis glycosides or certain anti-arrhythmic medicinal products.</p><p>No information is available regarding the dialysability of olmesartan or hydrochlorothiazide.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p>Pharmacotherapeutic group: Angiotensin II antagonists and diuretics, ATC code: C09D A 08. <u>Mechanism of action / Pharmacodynamic effects</u></p><p>Co-Olmepress is a combination of an angiotensin II receptor antagonist, olmesartan medoxomil, and a thiazide diuretic, hydrochlorothiazide. The combination of these ingredients has an additive antihypertensive effect, reducing blood pressure to a greater degree than either component alone.</p><p>Once daily dosing with Co-Olmepress provides an effective and smooth reduction in blood pressure over the 24 hour dose interval.</p><p><u>Olmesartan medoxomil </u>is an orally active, selective angiotensin II receptor (type AT1) antagonist. Angiotensin II is the primary vasoactive hormone of the renin-angiotensin-aldosterone system and plays a significant role in the pathophysiology of hypertension. The effects of angiotensin II include vasoconstriction, stimulation of the synthesis and release of aldosterone, cardiac stimulation and renal reabsorption of sodium. Olmesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by blocking its binding to the AT1&nbsp;receptor in tissues including vascular smooth muscle and the adrenal gland. The action of olmesartan is independent of the source or route of synthesis of angiotensin II. The selective antagonism of the angiotensin II (AT1) receptors by olmesartan results in increases in plasma renin levels and angiotensin I and II concentrations, and some decrease in plasma aldosterone concentrations.</p><p>In hypertension, olmesartan medoxomil causes a dose-dependent, long-lasting reduction in arterial blood pressure. There has been no evidence of first-dose hypotension, of tachyphylaxis during long-term treatment, or of rebound hypertension after abrupt cessation of therapy.</p><p>Once daily dosing with olmesartan medoxomil provides an effective and smooth reduction in blood pressure over the 24 hour dose interval. Once daily dosing produced similar decreases in blood pressure as twice daily dosing at the same total daily dose.</p><p>With continuous treatment, maximum reductions in blood pressure are achieved by 8 weeks after the initiation of therapy, although a substantial proportion of the blood pressure lowering effect is already observed after 2 weeks of treatment.</p><p>The effect of olmesartan medoxomil on mortality and morbidity is not yet known.</p><p>The Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study in 4447 patients with type 2 diabetes, normo-albuminuria and at least one additional cardiovascular risk factor, investigated whether treatment with olmesartan could delay the onset of microalbuminuria. During the median follow-up duration of 3.2 years, patients received either olmesartan or placebo in addition to other antihypertensive agents, except ACE inhibitors or ARBs.</p><p>For the primary endpoint, the study demonstrated a significant risk reduction in the time to onset of microalbuminuria, in favour of olmesartan. After adjustment for BP differences this risk reduction was no longer statistically significant. 8.2% (178 of 2160) of the patients in the olmesartan group and 9.8% (210 of 2139) in the placebo group developed microalbuminuria.</p><p>For the secondary endpoints, cardiovascular events occurred in 96 patients (4.3%) with olmesartan and in 94 patients (4.2%) with placebo. The incidence of cardiovascular mortality was higher with olmesartan compared to placebo treatment (15 patients (0.7%) vs. 3 patients (0.1%)), despite similar rates for non-fatal stroke (14 patients (0.6%) vs. 8 patients (0.4%)), non-fatal myocardial infarction (17 patients (0.8%) vs. 26 patients (1.2%)) and non-cardiovascular mortality (11 patients (0.5%) vs. 12 patients (0.5%)). Overall mortality with olmesartan was numerically increased (26 patients (1.2%) vs. 15 patients (0.7%)), which was mainly driven by a higher number of fatal cardiovascular events.</p><p>The Olmesartan Reducing Incidence of End-stage Renal Disease in Diabetic Nephropathy Trial (ORIENT) investigated the effects of olmesartan on renal and cardiovascular outcomes in 577 randomized Japanese and Chinese type 2 diabetic patients with overt nephropathy. During a median follow-up of 3.1 years, patients received either olmesartan or placebo in addition to other antihypertensive agents including ACE inhibitors.</p><p>&nbsp;</p><p>The primary composite endpoint (time to first event of the doubling of serum creatinine, end-stage renal disease, all- cause death) occurred in 116 patients in the olmesartan group (41.1%) and 129 patients in the placebo group (45.4%) (HR 0.97 (95% CI 0.75 to 1.24); p=0.791). The composite secondary cardiovascular endpoint occurred in 40 olmesartan- treated patients (14.2%) and 53 placebo-treated patients (18.7%). This composite cardiovascular endpoint included cardiovascular death in 10 (3.5%) patients receiving olmesartan versus 3 (1.1%) receiving placebo, overall mortality 19 (6.7%) versus 20 (7.0%), non-fatal stroke 8 (2.8%) versus 11 (3.9%) and non-fatal myocardial infarction 3 (1.1%) versus 7 (2.5%), respectively.</p><p><u>H</u>ydrochlorothiazide is a thiazide diuretic. The mechanism of the antihypertensive effect of thiazide diuretics is not fully known. Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts. The diuretic action of hydrochlorothiazide reduces plasma volume, increases plasma renin activity and increases aldosterone secretion, with consequent increases in urinary potassium and bicarbonate loss, and decreases in serum potassium. The renin-aldosterone link is mediated by angiotensin II and therefore coadministration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with thiazide diuretics. With hydrochlorothiazide, onset of diuresis occurs at about 2 hours and peak effect occurs at about 4 hours post-dose, whilst the action persists for approximately 6-12 hours.</p><p>Epidemiological studies have shown that long-term treatment with hydrochlorothiazide monotherapy reduces the risk of cardiovascular mortality and morbidity.</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape id="_x0000_s1026" style='position:absolute;
 margin-left:160.65pt;margin-top:15.6pt;width:1.3pt;height:1pt;z-index:-251650048;
 mso-position-horizontal-relative:page;mso-position-vertical-relative:text'
 coordsize="26,20" o:allowincell="f" path="m,7hhl25,7e" filled="f"
 strokeweight=".29886mm">
 <v:path arrowok="t"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="4" height="2" src="file:///C:/Users/Moustafa/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png" /><u>Clinical efficacy and safety</u></p><p><u>The combination of olmesartan medoxomil and h</u>ydrochlorothiazide produces additive reductions in blood pressure which generally increase with the dose of each component. In pooled placebo-controlled studies, administration of the 20/12.5 mg and 20 /25 mg combinations of olmesartan medoxomil/hydrochlorothiazide resulted in mean placebo- subtracted systolic/diastolic blood pressure reductions at trough of 12/7 mmHg and 16/9 mmHg, respectively. Age and gender had no clinically relevant effect on response to treatment with olmesartan medoxomil/hydrochlorothiazide combination therapy.</p><p>Administration of 12.5 mg and 25 mg hydrochlorothiazide in patients insufficiently controlled by olmesartan medoxomil 20 mg monotherapy gave additional reductions in 24-hour systolic/diastolic blood pressures measured by ambulatory blood pressure monitoring of 7/5 mmHg and 12/7 mmHg, respectively, compared with olmesartan medoxomil monotherapy baseline. The additional mean systolic/diastolic blood pressure reductions at trough compared with baseline, measured conventionally, were 11/10 mmHg and 16/11 mmHg, respectively.</p><p>The effectiveness of olmesartan medoxomil/hydrochlorothiazide combination therapy was maintained over long-term (one-year) treatment. Withdrawal of olmesartan medoxomil therapy, with or without concomitant hydrochlorothiazide therapy, did not result in rebound hypertension.</p><p>The effects of fixed dose combination of olmesartan medoxomil/hydrochlorothiazide on mortality and cardiovascular morbidity are currently unknown.</p><p>&nbsp;</p><p><u>Other information:</u></p><p>Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) have examined the use of the combination of an ACE-inhibitor with an angiotensin II receptor blocker.</p><p>ONTARGET was a study conducted in patients with a history of cardiovascular or cerebrovascular disease, or type 2 diabetes mellitus accompanied by evidence of end-organ damage. VA NEPHRON-D was a study in patients with type 2 diabetes mellitus and diabetic nephropathy.</p><p>These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes and mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as compared to monotherapy was observed. Given their similar pharmacodynamic properties, these results are also relevant for other ACE-inhibitors and angiotensin II receptor blockers.</p><p>ACE-inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly in patients with diabetic nephropathy.</p><p>ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both. The study was terminated early because of an increased risk of adverse outcomes. Cardiovascular death and stroke were both numerically more frequent in the aliskiren group than in the placebo group and adverse events and serious adverse events of interest (hyperkalaemia, hypotension and renal dysfunction) were more frequently reported in the aliskiren group than in the placebo group.</p><p>Non-melanoma skin cancer:</p><p>Based on available data from epidemiological studies, cumulative dose-dependent association between HCTZ and NMSC has been observed. One study included a population comprised of 71,533 cases of BCC and of 8,629 cases of SCC matched to 1,430,833 and 172,462 population controls, respectively. High HCTZ use (&ge;50,000 mg cumulative) was associated with an adjusted OR of 1.29 (95% CI: 1.23-1.35) for BCC and 3.98 (95% CI: 3.68-4.31) for SCC. A clear cumulative dose response relationship was observed for both BCC and SCC. Another study showed a possible association between lip cancer (SCC) and exposure to HCTZ: 633 cases of lip-cancer were matched with 63,067 population controls, using a risk-set sampling strategy. A cumulative dose-response relationship was demonstrated with an adjusted OR 2.1 (95% CI: 1.7-2.6) increasing to OR 3.9 (3.0-4.9) for high use (~25,000 mg) and OR 7.7 (5.7-10.5) for the highest cumulative dose (~100,000 mg) (see also section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption and distribution</u></p><p><em>Olmesartan medoxomil:</em></p><p>Olmesartan medoxomil is a prodrug. It is rapidly converted to the pharmacologically active metabolite, olmesartan, by esterases in the gut mucosa and in portal blood during absorption from the gastrointestinal tract. No intact olmesartan medoxomil or intact side chain medoxomil moiety have been detected in plasma or excreta. The mean absolute bioavailability of olmesartan from a tablet formulation was 25.6%.</p><p>The mean peak plasma concentration (Cmax) of olmesartan is reached within about 2 hours after oral dosing with olmesartan medoxomil, and olmesartan plasma concentrations increase approximately linearly with increasing single oral doses up to about 80 mg.</p><p>Food had minimal effect on the bioavailability of olmesartan and therefore olmesartan medoxomil may be administered with or without food.</p><p>No clinically relevant gender-related differences in the pharmacokinetics of olmesartan have been observed.</p><p>Olmesartan is highly bound to plasma protein (99.7%), but the potential for clinically significant protein binding displacement interactions between olmesartan and other highly bound coadministered active substances is low (as confirmed by the lack of a clinically significant interaction between olmesartan medoxomil and warfarin). The binding of olmesartan to blood cells is negligible. The mean volume of distribution after intravenous dosing is low (16 &ndash; 29 L).</p><p><em>Hydrochlorothiazide:</em></p><p>Following oral administration of olmesartan medoxomil and hydrochlorothiazide in combination, the median time to peak concentrations of hydrochlorothiazide was 1.5 to 2 hours after dosing. Hydrochlorothiazide is 68 % protein bound in the plasma and its apparent volume of distribution is 0.83 &ndash; 1.14 L/kg.</p><p><u>Biotransformation and elimination</u></p><p><em>Olmesartan medoxomil:</em></p><p>Total plasma clearance of olmesartan was typically 1.3 L/h (CV, 19%) and was relatively slow compared to hepatic blood flow (ca 90 L/h). Following a single oral dose of 14C-labelled olmesartan medoxomil, 10 - 16% of the administered radioactivity was excreted in the urine (the vast majority within 24 hours of dose administration) and the remainder of the recovered radioactivity was excreted in the faeces. Based on the systemic availability of 25.6%, it can be calculated that absorbed olmesartan is cleared by both renal excretion (ca 40%) and hepato-biliary excretion (ca 60%). All recovered radioactivity was identified as olmesartan. No other significant metabolite was detected. Enterohepatic recycling of olmesartan is minimal. Since a large proportion of olmesartan is excreted via the biliary route, use in patients with biliary obstruction is contraindicated (see section 4.3).</p><p>The terminal elimination half life of olmesartan varied between 10 and 15 hours after multiple oral dosing. Steady state was reached after the first few doses and no further accumulation was evident after 14 days of repeated dosing. Renal clearance was approximately 0.5 &ndash; 0.7 L/h and was independent of dose.</p><p><em>Hydrochlorothiazide:</em></p><p>Hydrochlorothiazide is not metabolised in man and is excreted almost entirely as unchanged active substance in urine. About 60% of the oral dose is eliminated as unchanged active substance within 48 hours. Renal clearance is about 250&ndash; 300 mL/min. The terminal elimination half-life of hydrochlorothiazide is 10 &ndash; 15 hours.</p><p>Co-Olmepress</p><p>The systemic availability of hydrochlorothiazide is reduced by about 20% when co-administered with olmesartan medoxomil, but this modest decrease is not of any clinical relevance. The kinetics of olmesartan are unaffected by the co-administration of hydrochlorothiazide.</p><p><u>Pharmacokinetics in special populations</u></p><p><em>Elderly (age 65 years or over)</em>:</p><p>In hypertensive patients, the olmesartan AUC at steady state was increased by ca 35% in elderly people (65 &ndash; 75 years old) and by ca 44% in very elderly people (&ge; 75 years old) compared with the younger age group (see section 4.2).</p><p>Limited data suggest that the systemic clearance of hydrochlorothiazide is reduced in both healthy and hypertensive elderly people compared to young healthy volunteers.</p><p><em>Renal impairment:</em></p><p>In renally impaired patients, the olmesartan AUC at steady state increased by 62%, 82% and 179% in patients with mild, moderate and severe renal impairment, respectively, compared to healthy controls (see sections 4.2, 4.4).</p><p>The half-life of hydrochlorothiazide is prolonged in patients with impaired renal function.</p><p>&nbsp;</p><p><em>Hepatic impairment:</em></p><p>After single oral administration, olmesartan AUC values were 6% and 65% higher in mildly and moderately hepatically impaired patients, respectively, than in their corresponding matched healthy controls. The unbound fraction of olmesartan at 2 hours post-dose in healthy subjects, in patients with mild hepatic impairment and in patients with moderate hepatic impairment was 0.26%, 0.34% and 0.41%, respectively. Following repeated dosing in patients with moderate hepatic impairment, olmesartan mean AUC was again about 65% higher than in matched healthy controls.</p><p>Olmesartan mean Cmax&nbsp;values were similar in hepatically-impaired and healthy subjects. Olmesartan medoxomil has not been evaluated in patients with severe hepatic impairment (see sections 4.2, 4.4).</p><p>Hepatic impairment does not significantly influence the pharmacokinetics of hydrochlorothiazide<strong><em>.</em></strong></p><p>Drug interactions</p><p><em>Bile acid sequestering agent colesevelam:</em></p><p>Concomitant administration of 40 mg olmesartan medoxomil and 3750 mg colesevelam hydrochloride in healthy subjects resulted in 28% reduction in Cmax&nbsp;and 39% reduction in AUC of olmesartan. Lesser effects, 4% and 15% reduction in Cmax&nbsp;and AUC respectively, were observed when olmesartan medoxomil was administered 4 hours prior to colesevelam hydrochloride. Elimination half life of olmesartan was reduced by 50 &ndash; 52% irrespectively of whether administered concomitantly or 4 hours prior to colesevelam hydrochloride (see section 4.5).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The toxic potential of olmesartan medoxomil/hydrochlorothiazide combinations was evaluated in repeated dose oral toxicity studies for up to six months in rats and dogs.</p><p>As for each of the individual substances and other medicinal products in this class, the main toxicological target organ of the combination was the kidney. The combination of olmesartan medoxomil/hydrochlorothiazide induced functional renal changes (increases in serum urea nitrogen and in serum creatinine). High dosages caused tubular degeneration and regeneration in the kidneys of rats and dogs, probably via a change in renal haemodynamics (reduced renal perfusion resulting from hypotension with tubular hypoxia and tubular cell degeneration). In addition, the olmesartan medoxomil/ hydrochlorothiazide combination caused a decrease in red blood cell parameters (erythrocytes, haemoglobin and haematocrit) and a reduction in heart weight in rats.</p><p>These effects have also been observed for other AT1&nbsp;receptor antagonists and for ACE inhibitors and they seem to have been induced by the pharmacological action of high dosages of olmesartan medoxomil and seem to be not relevant to humans at the recommended therapeutic doses.</p><p>Genotoxicity studies using combined olmesartan medoxomil and hydrochlorothiazide as well as the individual components have not shown any signs of a clinically relevant genotoxic activity.</p><p>The carcinogenic potential of a combination of olmesartan medoxomil and hydrochlorothiazide was not investigated as there was no evidence of relevant carcinogenic effects for the two individual components under conditions of clinical use.</p><p>There was no evidence of teratogenicity in mice or rats treated with olmesartan medoxomil/hydrochlorothiazide combinations. As expected from this class of medicinal product, fetal toxicity was observed in rats, as evidenced by significantly reduced fetal body weights, when treated with olmesartan medoxomil/hydrochlorothiazide combinations during gestation (see sections 4.3, 4.6).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Tablet core </em></p><p><em>Microcrystalline cellulose </em></p><p><em>Lactose monohydrate</em></p><p><em>Povidone</em></p><p><em>Hydroxypropylcellulose</em></p><p><em>Magnesium stearate</em></p><p><em>&nbsp;</em></p><p><em>Tablet coat </em></p><p><em>OpadryY-1-7000</em></p><p><em>Yellow iron oxide</em></p><p><em>Red iron oxide</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aluminium blister</p><p>Co-Olmepress 40 mg/25 mg is supplied in packages containing 28 tablets (7-tablets blister packs).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p>No special requirements<em>.</em></p><p><em>&nbsp;</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
LABORATORIOS CINFA, S.A. 
Olaz-Chipi, 10 - Polígono Areta 
31620 Huarte - Pamplona (Navarra). SPAIN

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                11/2018
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>